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1 Introduction and Outline of the Thesis 
Prostate cancer represents an important health problem in most western 
countries. In the Netherlands, incidence and mortality of prostate cancer are 
exceeded only by those of lung cancer. In 1989, 4,112 incident cases and 2,079 
deaths from cancer of the prostate were recorded in a male population of 7.5 
million. [1,2]. In most western countries the incidence increases with increasing 
age of the population, and doctors but especially patients awareness of the 
disease. In the USA, prostate cancer incidence rate increased by 6.4% per year 
between 1983 and 1989 [3]. The number of patients with occult prostate cancer 
exceeds by far the number of patients with clinically apparent tumors. Occult 
tumors (latent, clinically silent cancers discovered at autopsy) occur in up to 40% 
of patients in the eight decade of life whereas the incidence of clinically signif-
icant tumors is 0,04% at the age of 50 years rising to 1,4% at the age of 80 years [4]. 
Prostate cancer may be cured if detected at an early stage. This entails that the 
tumor should not extend beyond the capsule of the prostate and that there are 
no distant metastases. More sensitive diagnostic tools such as prostate-specific 
antigen (PSA) and transrectal ultrasound (TRUS) combined with ultrasound 
guided biopsies have led to an increased number of cancers detected at an early 
stage. However, because prostate cancer is often a slowly-growing, indolent tumor 
a number of patients will not require treatment. Therefore Whitmore's question 
"Is cure possible for whom it is neccessary and is cure neccessary for whom it is 
possible?" is still relevant [5]. This thesis deals to a large extent with the question 
of whether magnetic resonance (MR) imaging is capable of selecting the patients 
for whom cure is possible? 
The extent of prostate cancer is assessed preoperatively by clinical staging, the 
definitive staging is being achieved by histopathologic examination. In chapter 
2, the objective, value and controversies of clinical and pathological local staging 
are discussed. The pathological stage is not the only predictor of outcome in a 
patient with prostate cancer. Attention is payed to other prognostic factors such 
as tumor volume, histologic grade, and neo-vascularity. 
MR is an important modality for evaluating prostate cancer [6]. With the 
introduction of an endorectal surface coil (ERC) the prostate can be imaged with 
a higher resolution and an increased signal-to-noise ratio [7]. In chapter 3 the 
results of local staging in 34 patients are described. Furthermore we evaluated 
the potential of MR imaging with an ERC technique in the assessment of tumor 
volume. One of the pitfalls of MR imaging with an ERC is discussed in an inter-
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lude, a repor t of a case of senile amyloidosis of the seminal vesicles mimicking 
seminal vesicle invasion on ERC-MR images. 
When lymph node metastases occur, the patient is no longer considered a 
candidate for curative surgical treatment. Chapter 4 reports the results of a 3-
dimensional (3D) MR imaging technique in the evaluation of pelvic lymph nodes 
in 134 patients with prostate or bladder cancer. Lymph node metastases may 
become evident by enlargment of the node. However, a considerable number of 
lymph node metastases occur in non-enlarged lymph nodes. These are generally 
detected dur ing operation on frozen section examination of the specimen. The 
finding of positive lymph nodes is diminishing rapidly as today, more patients are 
diagnosed in an early stage. Therefore some investigators suggest that there is no 
place for imaging in the preoperative evaluation of patients who are candidates 
for a radical prostatectomy. The second interlude, a letter to CANCER, contains 
a comment on an article in which is suggested that there is no role for imaging 
in nodal staging of prostate cancer. It is argued that there is a role for imaging of 
lymph nodes in a selected group of patients who are candidate for curative 
therapy. The reply of the author is included. 
We postulated that with the use of newer MR techniques such as dynamic imag-
ing and spectroscopy, more accurate information about stage, grade, tumor volume 
and biological potential of the tumor would become available. In chapter 5 we 
evaluate the potential of a dynamic MR imaging technique following the injec-
tion of contrast material. The imaging results of 57 patients were compared with 
the final histopathology with respect to tumor location and capsular penetrat ion. 
With MR proton spectroscopy it became possible to obtain in vivo information 
about the presence of certain metabolites (citrate, choline, creatine) in the 
prostate. Chapter 6 extensively reports the results of this technique in healthy 
volunteers. In chapter 7 the results of MR proton spectroscopy in patients with 
benign prostatic hyperplasia (BPH) and prostate cancer are reported. 
Chapter 8 is a concise discussion about the current role of MR in patients with 
prostate cancer and contains recommendat ions for future studies. 
In Chapter 9 the summary and conclusions are presented. 
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Abstract 
Staging prostate cancer is a systemic classification of the extent of disease based 
on clinical and pathological criteria. Despite the general acceptation of the TNM 
staging system, a lot of controversies and uncertainty, with respect to staging, still 
exist. This paper gives an overview of different staging modalities and emphasizes 
the need for incorporation of prognostic factors, such as tumor grade and tumor 
volume, in the staging system. 
Key Words; prostate, prostate neoplasm, prostate cancer staging, staging 
controversies 
Introduction 
Prostate cancer is the most commonly diagnosed noncutaneous cancer in men 
and the second leading cause of cancer related deaths. The age-specific mortality 
rate for prostate cancer has increased steadily during the last 30 years and with the 
availibility of highly sensitive techniques to detect serum prostate specific antigen 
(PSA) the incidence has increased dramatically during the last 5 years [ 1 ]. 
The best treatment for localized prostate cancer is still under debate [2-6]. The 
mainstay for prostate cancer control is radical surgery in patients with organ-con­
fined disease [7]. Alternative treatments for localized disease are (curative) 
radiotherapy [8], cryosurgery [9,10] and deferred treatment (watchfull waiting) 
[3,11]. For tumor that extends beyond the pseudocapsule or in cases with metas­
tases "hormonal ablation" is a treatment option [2]. 
Ideally, clinical staging stratifies patients into comparable groups for definitive 
therapy and allows comparison of the effectiveness of different therapies, 
whereas pathological staging is important to predict prognosis and the need for 
additional therapy. 
In 1992, the American Joint Committee on Cancer (AJCC), in collaboration 
with the International Union Against Cancer (IUCC) adapted a revision of the 
TNM staging system (table 1) [12]. The revision permitted transition from the 
classical Whitmore ABCD system to the TNM classification: for example stage A 
becomes Tl , stage В becomes T2 and stage С becomes T3. 
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Table 1. TNM classification- Primary tumor (T) 1992 revision [12] 
TX Primary tumor cannot be assessed 
TO No evidence of primary tumor 
T1 Clinically apparent tumor, not palpable nor visible by imaging 
- T1 a Tumor is incidental histologic finding in 5% or less of tissue resected 
- T1 b Tumor is incidental finding in more than 5% 
- T1 с Tumor identified by needle biopsy (due to elevated serum PSA) 
T2 Tumor palpable or visible by imaging confined to the prostate 
- T2a Tumor involves half of a lobe or less 
- T2b Tumor involves more than half of a lobe but not both lobes 
- T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule 
- T3a Unilateral extracapsular extension 
- T3b Bilateral extracapsular extension 
- T3c Tumor invades seminal vesicles 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles 
- T4a Tumor invades bladder neck and/or external sphincter and/or rectum 
- T4b Tumor invades levator muscles and/or is fixed to pelvic wall 
Other changes in 1992 included the definition of a Tic subcatagory to 
describe prostate cancer discovered by biopsy prompted by an elevated prostate 
specific antigen (PSA) level, to allow Τ classification by imaging and to group 
disease with capsular invasion without penetration from the pT3 category in the 
1987 edition, into the pT2 category. 
Anatomy 
The prostate can be divided into four glandular zones: the peripheral zone (PZ), 
central zone (CZ), transition zone (TZ) and periurethral zone. Most of the 
peripheral glandular units of the prostate do not reach the outer margin of the 
prostate. They are separated from the periprostatic connective tissue by a 2- to 3-
mm band of stromal tissue of concentrali)7 placed fibromuscular tissue, the so-
called prostatic capsule. This is not a capsule in the strict sense, but an inseparable 
component of the prostatic tissue. At the apex the capsule is no longer present 
facilitating extra-capsular tumor growth [13]. 
Seventy percent of tumors arise in the PZ. Tumors arising in the PZ can be seen 
by Transrectal Ultrasound (TRUS) and Magnetic Resonance (MR) imaging [14]. 
About 10% of the cancers arise in the CZ, and approximately 20% arise in the 
TZ. The TZ is the site of origin of benign prostatic hyperplasia (BPH) and there­
fore often comprises a much larger portion of the gland in older men [15]. It is 
often difficult to distuinguish BPH and cancers in die TZ by MRI and TRUS [16]. 
Primary staging 
The goal of primary staging is to determine the local extent of disease, the Τ 
category. In general practice it is important to determine which patients are 
candidate for curative therapy on account of locally confined disease. 
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Digital rectal examination (DRE) 
Historically, DRE plays a central role in local staging. Although the findings of 
DRE are so wide-spread used there are little data available on the reliability of 
DRE in clinical staging [ 17]. There are no data of intra-or inter observer variabil-
ity. Data accumulated from carefully examined prostatectomy specimens 
revealed that DRE underestimated the local extent of cancer in 40-60% of cases 
[18,19]. Most of the understaging is based on microscopic penetrat ion of the 
capsule or invasion in the seminal vesicles. 
Prostate Specific Antigen (PSA) 
PSA is the most accurate marker to screen for prostate cancer but has limited 
accuracy in staging because there is a substantial overlap in PSA concentrat ions 
and pathologic stages. Nevertheless the combination of serum PSA concentration 
and other variables like tumor grade, volume and clinical stage, significantly 
enhance the predictive value of serum PSA for the pathological stage [20]. 
TRUS 
TRUS has become essential for the diagnosis of disease in a short period of time, 
although for staging TRUS is not generally accepted. TRUS has the advantage of 
allowing visualization of cancers as a hypoechoic lesion in the PZ in many cases 
(fig.l). Capsular penetrat ion is diagnosed by local contour deformity a n d / o r 
interruption of the periprostatic fat echos [21] (fig. 2). 
There is considerable inter and intra observer variability in the assignment of 
clinical stage. Detection of microscopic extension of prostate cancer is beyond 
the capabilities of TRUS [22]. Despite the widespread use, the role of TRUS in 
staging prostate cancer had not yet been established [17]. In the study of Rifkin 
et al. [21] the overall accuracy was 58%. Correct staging was achieved in 46% of 
Figure 1. Trans rectal ultra-
sonography of a T2 carcinoma. 
The carcinoma is visualised as 
a hypoechoic lesion in the 
perlperal zone (arrows). 
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Figure 2. Trans rectal ultra­
sonography shows a ТЗ tu­
mor on the left side (arrows). 
Capsular penetration Is de­
monstrated as a local contour 
deformity (small arrows). 
localized and 66% of advanced cancers. The advantage of TRUS compared to 
MR imaging, is that it allows directed biopsies of suspected lesions and of the 
seminal vesicles, thus improving staging [23]. 
Computed Tomography (CT) 
CT does not allow direct visualization of prostate cancer and is considered of little 
value in local staging [24]. The role of CT is limited to nodal staging [25]. 
MR Imaging 
MR imaging provides the best depiction of the anatomy of the prostate and 
seminal vesicles. The internal architecture is clearly visible on T2-weighted 
images. Prostate cancer is usually visible as a low signal intensity lesion in a bright 
peripheral zone. The capsule is visible as a low signal intensity rim (fig. 3). 
Capsular perforation is most often visible as a disruption of the prostatic cap­
sule and infiltration of the periprostatic fat. Seminal vesicle invasion is visible as 
an abnormal low signal intensity within the lumen of the seminal vesicle (fig. 4). 
MR imaging using traditional body coils (fig. 5) has been disappointing in stag­
ing of prostate cancer and is not superior to TRUS. The reported accuracy was 
69% [21]. The accuracy of MR imaging with an endorectal coil was initially 
reported 82% [26]. However, more recent data suggest a lower accuracy level, 
almost equal to the body coil technique [27]. 
Further evaluation of MR imaging is obviated because of the continuing devel­
opment of fast imaging sequences and new coils. A recent study of MR imaging 
with an integrated endorectal pelvic phased-array coil [28] reported an accuracy 
rate of 76%. 
Pathologic staging 
Pathologic staging is the best prognostic marker to date and far more accurate 
than clinical staging. It should be noted however, that the pathologic stage may 
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Figure 3. Endorectal coil MR 
¡mage of the prostate. Trans-
axial T2-weighted ¡mage 
demonstrating prostate can-
cer as a low signal Intensity 
lesion In the bright peripheral 
zone (small arrow). The caps-
ule is visible as a low signal 
Intensity rim. Note the presen-
ce of BPH In the central zone 
(large arrow). BPH has signal 
intensity almost equal comp-
ared to cancer. 
Figure 4. Coronal T2-welght-
ed image of the prostate 
obtained with an endo-rectal 
coil. Large T3 tumor on the 
left side. Note capsular per-
foration and abnormal low 
signal intensity within the 
lumen of the seminal vesicle 
(arrow) representing tumor 
Invasion of the seminal ves-
icles. 
depend on the way the radical prostatectomy specimen is examined. For 
example, whole-mount sectioning increases the number of capsular penetration 
sites compared to random sectioning [29,30]. 
Secondly, Epstein et al. [31] reported that when urologists review pathology 
reports, these may be misunderstood in a number of cases. This is due to the 
amount of often imprecise terms used to describe involvement of the capsule, 
such as invasion, extension into, penetration, permeation, transgression and the 
use of adjectives such as focal, microscopic, minimal and gros perforation. 
Figure 5. Transaxial T2-
weighted MR image obtained 
with a body coil shows a low 
signal intense area in the peri­
pheral zone (arrow). The lesi­
on was found at radical pros­
tatectomy to represent a T2 
prostate cancer. Note that 
due to the lower resolution, 
the capsule is less easy to 
define than on endo-rectal 
coil images. 
Discussion 
Increasing costs of healthcare have caused a critical view on staging of prostate 
cancer. The number of patients with localized cancer is rapidly increasing caus­
ing an enormous increase of costs when all staging modalities are performed. 
The way to assess the clinical status varies from institution to institution. PSA, 
grade and DRE may be used to tailor the diagnostic work-up in patients with 
prostate cancer. The additional value of MR imaging, although considered the 
best imaging modality in the primary staging of prostate cancer, is often limited. 
A recent study demonstrated that MR imaging for local staging is valuable for the 
subgroup of patients with a PSA between 10-20 ng/ and Gleasons score of 5 to 7 
[32]. 
Despite the widespread acceptance of the 1992 AJCC/UICC TNM staging 
classification, areas of controversy and uncertainty exist. The role that imaging 
should play is still debatable. For example what should be the clinical stage of a 
patient with one palpable node (T2a), that TRUS can not define while sextant 
bipsies reveal bilateral disease (uTlc) and finally MR imaging demonstrates one 
lesion contralateral to the index lesion with evidence of capsular penetration 
(mT3a). Because there is such wide divergence in the medical community on the 
reliability of prostatic imaging, there will be inconsistency in staging. Some urol­
ogists disregard imaging findings to a large extend and rely only on DRE to assign 
a clinical Τ stage [33]. 
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Prognostic factors 
Another area of uncertainty is that the natural history of disease or response to 
therapy of a patient cannot be predicted by stage alone. Patients with the same 
clinical or pathological stage may not have the same clinical outcome and 
reversed, patient with different pathological stage may have the same prognosis. 
E.g. the prognosis of a patient with prostate cancer is not affected by focal cap-
sular penetration (pT3) and comparable to a patient with a pT2 tumor [31]. 
Pathological stage is the single most powerfull prognostic variable [7], but also 
other factors such as grade, tumor volume [34], and other molecular, tumor-cell 
specific markers such as DNA ploidy [35], nuclear morphometry [36], PSA level 
[37] and neovascularisation [38] strongly influence prognosis and therefore 
should be included into the staging algorithme [6]. Unfortunately the TNM 
system is not well designed to accomodate additional variables. 
Tumor volume 
It is stated that if tumor volume is smaller than 4cc metatasis are unlikely whereas 
with a tumor volume of more than 12cc metastases are highly likeky [39]. DRE, 
TRUS and MR images with standard body coil and conventional SE techniques 
have not been accurate in preoperatively estimating tumor volume [40-46]. FSE 
MR images obtained with a phased-array coil showed a belter estimation of tumor 
volume [47]. Initial experience with dynamic Tl-weighted single slice technique 
following intravenous contrast with a high time resolution (1 image/sec) suggest 
that a better delineation of prostate cancer volume may be possible [ 48]. 
Gleason grade 
No imaging method provides information on Gleason grade. Biopsies can 
provide information about tumor grade, however because prostate cancer is a 
heterogeneous tumor, grade is even difficult to assess with multiple biopsies. 
In vivo proton MR spectroscopy demonstrates a relation between the citrate 
level and grade. Low citrate concentration correlates well with poorly differ-
entiated tumors [49]. 
Neovascularity 
There is an increased density of capillairies in prostatic carcinoma compared to 
benign prostatic tissue. The number of microvessels is related to the prognosis 
[38]. To date it is not clear whether imaging can demonstrate the neovascularity. 
Color doppler US can show flow in larger vessels but not in capillairies. This tech-
nique may be usefull to increase the specificity of TRUS in detecting prostate can-
cer [50]. 
With late postcontrast MR imaging no differentiation between prostate cancer 
and normal glandular tissue can be demonstrated, but with dynamic MR imaging 
using a fast imaging technique, differentiation may be possible due to early and 
rapid enhancement of prostate cancer [48]. The relation of this enhancement 
pattern and microvessel density is still under investigation. 
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Conclusion 
Allthough the revised TNM staging system allows imaging results to play a role in 
the description of a local lesion they play still a limited role 
No preoperative primary staging methods however, will accurately predict 
pathologic stage n o r clinical outcome Therefore, staging classification needs to 
be flexible to incorporate o ther prognostic factors 
Fur ther evaluation of the preoperative assessment of stage and prognostic 
factors with new techniques like dynamic MR imaging and MR spectroscopy is 
n e e d e d 
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Abstract 
Objective 
To evaluate the accuracy of MR imaging of the prostate with an endorectal sur­
face coil in determining presence, localization, volume, and local stage of prostate 
carcinoma. 
Subjects and Methods 
MR images of 34 patients with biopsy-proven cancer were correlated retrospect­
ively with the histologic mappings of radical prostatectomy specimens. The vol­
ume and number of tumor lesions on MR images were calculated and compared 
with the surgical specimens used as the gold standard. Tumor stage based on MR 
imaging was compared with the pathological stage according to the TN M class­
ification. Predictive values were calculated seperately for all lesions and for the 
lesions correctly localized with MR. 
Results 
MR imaging correctly depicted the location of 67% of the tumors. Twenty per­
cent of the lesions depicted by MR appeared to be false-positive errors. The 
tumors that were missed were located centrally and ventrally in the prostate. 
Tumor volume as shown by MR imaging was within a 25% range of the actual 
tumor volume in 10 cases, overestimated in 16 cases, and underestimated in eight 
cases. Histopathology showed capsular penetration in 12 of 34 patients (35%) 
and in 14 of 52 lesions (27%). Sensitivity, specificity, and positive predictive values 
were 43%, 84%, and 55%, respectively. Histologically, capsular penetration 
extended less than 1 mm into the periprostatic adipose tissue in seven patients. 
Sensitivity for capsular penetration less than 1 mm was 14%. Sensitivity tor caps­
ular penetration more than 1 mm was 71%. Accuracy for differentiating a pT2 
from a pT3 tumor was 68%. 
Conclusions 
Results from this study indicate that the accuracy of the technique was not satis­
factory for predicting actual tumor volume. Tumor detection and localization 
was more accurate in the peripheral zone than in the central zone. Accuracy was 
poor for detecting capsular penetraüon of less than 1 mm, but accuracy was 
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much better for penetration of more than 1 mm Because recent reports suggest 
that capsular penetration of less than 1 mm does not adversely affect surgical 
cure, MR imaging still may be pracücal in the selection of patients for radical 
prostatectomy 
Introduction 
The incidence of prostate cancer is still increasing The disease trails only lung 
cancer as the leading cause of death in men [1] Staging of prostate cancer is a 
systematic classification of the extent of disease based on clinical and pathologic 
entena Clinical stage is used to sort patients into comparable groups for definiüve 
therapy, whereas pathological stage is important in predicting prognosis and the 
need for additional therapy Curative treatment is considered possible only if the 
tumor is confined to the prostate gland (stage ^ T2) [2] Therefore, differen-
tiation between a T2 and a T3 tumor is of clinical importance On the other hand, 
several reports have stated that patients with minimal capsular penetration have 
a prognosis similar to that of paüents whose tumors are completely confined to 
the prostaüc capsule [3,4] 
It is süll not established what MR imaging technique results in the most accu-
rate diagnosis and preoperative staging Initially, the accuracy of body coil MR 
imaging with conventional spin-echo sequences was promising [5] Bodv coil MR 
imaging has the advantage that pelvic bones and lymph nodes can also be eval-
uated during the same session However, the signal-to-noise ratio and the spatial 
resolution are too low to provide high-resolution images of the prostate [6] 
With the recent development of an endorectal surface coil (FRC), the prostate 
and its surrounding structures are visualized much better [7] With fast spin-echo 
(FSE) techniques, T2-weighted images in three diffeient planes are obtained in 
a shorter time with a higher-resolution matnx and fewei motion artifacts than 
images obtained with conventional spin-echo sequences [8] The results is 
suggested, is improved staging accuracy 
Several recent studies have reported the results of MR imaging with ERC 
technique imaging for staging prostate cancer [7,9-16] Accuracy levels ranged 
from 54% to 83% In three of these studies, FSE MR images with an ERC were 
correlated with histopathologic mapping [12,14,16] 
As an adjunct to staging, the volume oí prostate cancer is also important for 
prognosis [17-19] When tumor volume is smaller than 4 cc, metatasis is very un-
likely whereas when tumor volume exceeds 12 cc metastases is highly likely [20] 
MR sequences with standard body coil and conventional spin-echo techniques 
have not given accurate images for estimating tumor volume before surgery 
[5,21-25] However FSE MR images obtained with a phased-array coil showed a 
better job of estimating of tumor volume [8] 
In our study we evaluate the diagnostic accuracy of MR imaging with FSE 
sequences that use an ERC to determine tumor presence, tumor volume, and the 
preoperative stage of prostate carcinoma In addition, we identify common pit-
falls of MR interpretation and the correlation of MR images with pathology 
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Subjects and Methods 
Patient population 
The study population was 34 patients with needle biopsy-proved adeno­
carcinoma. We performed MR imaging that used an ERC technique and followed 
that with radical retropubic prostatectomy. Patients mean age was 65 years old 
(range, 50-73 years). When biopsies preceded MR imaging, the average time was 
three weeks. Patients underwent radical prostatectomy within three weeks of 
imaging. Patients who underwent MR imaging and then received hormonal 
treatment before surgery were excluded from this study. All patients had clinical 
T2-3 disease according to the TNM classification (Table 1) [26]. We detected no 
lymph-node metastases in frozen sections at laparoscopic or open lymph-node 
dissection that preceded the radical prostatectomy. 
MR Technique 
All images were obtained using a 1.5 Τ Siemens SP system (Siemens, Erlangen, 
Germany), and a Medrad® endorectal coil (Medrad, Pittsburgh, PA). We placed 
the coil with the patient in the lateral decubitus position and inflated the coil with 
50-100 cc of air. Peristalsis was suppressed by Г administring 1 mg of glucagon. 
A tight band was wrapped around the patients abdomen to decrease respiratory 
movement. 
A sagittal Tl-weighted localized image was obtained to confirm coil position­
ing and to select locations for the axial images. Axial T-l weighted images 
(420/22[TR/ТЕ]) as well as axial, sagittal and coronal FSE T2-weighted images 
(2940/160[TR/ТЕ], echo-train length of 13) were performed. All examinations 
Table 1. TNM classification. Primary tumor (T) 1992 revision [26] 
Number of cases, figure in parentheses is the number correctly identified by MR 
TX Primary tumor cannot be assessed 
TO No evidence of primary tumor 
T1 Clinically apparent tumor, not palpable nor visible by imaging 
- T1 a Tumor is incidental histologic finding in 5% or less of tissue resected 
- T1 b Tumor is incidental finding in more than 5% 
- T1 с Tumor identified by needle biopsy (due to elevated serum PSA) 
T2 Tumor palpable or visible by imaging confined to the prostate 
- T2a Tumor involves half of a lobe or less 
- T2b Tumor involves more than half of a lobe but not both lobes 
- T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule 
- T3a Unilateral extracapsular extension 
- T3b Bilateral extracapsular extension 
- T3c Tumor invades seminal vesicles 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles 
- T4a Tumor invades bladder neck and/or external sphincter and/or rectum 
- T4b Tumor invades levator muscles and/or is fixed to pelvic wall 
Correct local staging by MR imaging as confirmed by histo-pathological examination according 
to TNM: 16/34 = 47% 
0(0) 
0(0) 
0(0) 
0(0) 
2(0) 
0(0) 
20(11) 
3(0) 
3(2) 
6(3) 
0(0) 
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were performed using a 4- or 5- mm slice thickness with a 1- or 2- mm gap, 26 cm 
field of view, and a 512 χ 216 matrix. An equalizing processing after application 
and a filter algorithm to compensate for near-field effect were also used. We also 
changed the phase encoding gradient to decrease motion artifacts over the 
prostate. An examination usually lasted 30 to 45 minutes. 
MR imaging examination 
The MR images were retrospectively interpreted by a single reader (G.J.) who had 
been interpreting MR examinations for prostate cancer and correlating the 
results with clinical and pathologic outcome for more than two years. The reader 
had no knowledge of the clinical findings, the PSA level, or the results of histo­
pathologic examination or transrectal sonography. Image quality was recorded 
with special regard to motion artifacts. An image was considered to be of poor 
quality when the delineation of the anatomic structures was degraded by motion 
artifacts. Good quality meant that these artifacts did not significantly degrade 
delineation of structures. 
On T2-weighted images, an area in the peripheral zone with a low signal 
intensity when compared with the adjacent peripheral zone was considered to be 
a malignancy. Low signal-intensity areas in the central zone were not interpreted 
as malignancy [27]. If a low signal intensity showed high signal on the corre­
sponding Tl-weighted image, the area was considered to be a hematoma. 
Tumors separated by more than 1 cm, without connection to another tumor 
in an adjacent section were interpreted as separate tumor lesions. Tumor volume 
was calculated by the sum of tumor areas multiplied by slice thickness, including 
gaps between slices. 
We used the following criteria to define capsular perforation: disruption of the 
prostatic capsule, infiltration of the periprostatic fat, low-signal-intensity strand­
ing, and involvement of the neurovascular bundle. A bulge in the contour or 
capsular thickening was not interpreted as capsular perforation [9,12]. Abnorm­
ally low signal intensity within the lumen of the seminal vesicle or focal thicken­
ing of the seminal wall was interpreted as seminal vesicle invasion [9]. Final 
staging was recorded according to the TNM classification (Table 1) [26]. 
Pathologic examination 
The prostatectomy specimens were in toto fixed overnight in a solution of 4% 
neutral buffered formalin. Step-sections were made at 4 mm intervals in a plane 
pai allei to the base of the prostate, which corresponded to the slices used on MR 
imaging. After separating the step-sections into right and left halves, all sections 
were routinely embedded in paraffin. Tissue sections of 5 pm were prepared and 
stained with hematoxylin and eosin. Regions representing cancer were outlined 
on the glass cover and retraced onto a diagram of the axial histologic sections 
that extended from the base to the apex of the prostate. To estimate tumor 
volume, the sum of the cancer areas on all sections was multiplied by 4 mm (slice 
thickness). The volume was then multiplied by a factor 1.1 to correct for tissue 
Local Staging of Prostate Cancer with Endorectal MR Imaging 19 
shrinkage due to fixation. Length and depth of penetration through the capsule 
and involvement of each seminal vesicle was recorded. Definitive staging was per­
formed with the TNM classification [26]. 
Data Analysis 
Analysis of the correlation of MR findings and histopathology were performed 
by a radiologist (GJ.) and a pathologist (E.R). The MR images were correlated 
with tumor maps that were based on the histopathologic sections. Tumor 
localization, number of tumors, tumor volume, status of the prostate capsule, 
involvement of each seminal vesicle, and definitive stage were evaluated. 
To offset the bias of incorrectly identified lesions (false positives), we analyzed 
matched lesions (true positives). A tumor location was considered to match if the 
tumor was present in the same craniocaudal third of the prostate (proximal, mid, 
or distal) and the tumor was localized in the same quadrant, regardless of the size 
of the lesion. Penetration through the capsule was compared for each tumor 
lesion. 
Results 
The endorectal coil was well-tolerated by all patients. In 28 patients, images 
obtained with the ERC provided detailed visualization of the prostate, prostatic 
capsule, and periprostatic structures, including the seminal vesicles. In six 
patients, image quality was poor due to motion artifacts caused by bowel motion 
(Λ=5) or due to upwards migration of the endorectal coil (Ai=l). Minor image 
degradation resulted from biopsy hematoma, high signal intensity close to the 
ERC (near-field effect), and shallow penetration depth of the ERC, however, 
image quality remained good. 
Pitfalls in correlating MR images with histopathologic findings 
The correlation between MR images and tumor maps based on histopathology 
was difficult in almost all patients. The most caudal section of MR images was 
0.5-1.5 cm lower than the section representing the apex in the prostatectomy 
specimen. Also, the angle by which the sections were cut was never exactly the 
same for either technique (difference 5°-15°). Furthermore, the shape of the 
prostate changed after fixation. Also making correlation difficult was the fact that 
the prostate tumors were markedly irregular and often demonstrated fingerlike 
projections with ill-defined margins that did not display on MR images of 4 or 5 
mm (while the histologic sections are only 4 pm thick). We tried to overcome 
these problems by using tumor maps, which gave a good three-dimensional 
picture of the prostate. We also employed our definition of a matched lesion. 
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Fig. 1. Bar graph shows the distribution of lesions determined with histopathology (solid bar) 
ranged in order of the actual tumor volume and the degree of match lesions (open bar), tumors 
less than 2cc easily remain undetected with MRI. 
Number and localization of tumor lesions 
A total of 44 separate tumor lesions were visualized with MR imaging and 52 were 
found on histopathologic examination of 34 patients (mean number of tumors, 
1.5; range 1-3). Thirty-four tumors were defined matched lesions (Fig. 1). In 10 
false-positive lesions identified by MR imaging, histopathology showed adjacent 
cystic changes in six cases. In four other false-positive lesions identified by MR 
imaging, histopathology failed to show an explanation for the low signal inten­
sity. 
MR imaging correctly depicted the location of 67% of the tumors. Twenty-two 
percent of the lesions depicted by MR appeared to be false-positive errors. 
Fourteen of the 18 tumors that were missed were located in the central or ventral 
part of the prostate. 
Tumor volume 
The accuracy of MR imaging in predicting tumor volume is presented in Figure 2. 
The mean volume of 44 tumor lesions captured on imaging with ERG was 2.3 
cc (range, 0.25-11.6 cc). The mean volume of 52 histopathologically detected 
lesions was 1.5 cc (range, 0.4-7.2 cc). When we compared only matched lesions, 
the mean volume was 2.6 cc by MR imaging with ERC and 1.8 cc by histopatho­
logy. In seven matched lesions, the tumor volume estimated by MR imaging fell 
within a 25% range of the actual volume. In 19 other cases, MR imaging over­
estimated the actual tumor volume by more than 25% (Fig. 3) and in eight other 
cases, the underestimation by MR imaging exceeded 25%. In the latter group, 
50% of the lesions were located in the central or ventral part of the prostate. 
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Fig. 2. Scatterplot shows 
poor correlation between vol-
ume determined by MR imag-
ing and the actual tumor vol-
ume. 
Fig. 3. Overestimating of tumor volume and underestimating of number of tumors in a 62-year-
old man. A, Axial fast-spin-echo T2-welghted ¡mage shows zone of decreased intensity on right 
(arrows), interpreted as carcinoma. The estimated volume was 3.3 cc. At pathologic examinati-
on there was almost symetrical bilateral tumor location. The calculated tumor volume both right 
and left was 0.7cc. B, Photograph of histopathologic section shows Adenocarcinoma diffusely 
growing between benign glands. 
Capsular penetration 
In 11 of 44 (25%) lesions identified by MR imaging, evidence of capsular 
penetration was stated. In 14 of 52 (27%) lesions detected by histopathology, 
capsular penetration was present. False-positive capsular penetration was present 
in four matched and in one false-positive lesion. Three cases of false-positive 
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Fig 4. Good correlation between MR imaging and pathology in a 57-year-old patient. 
A, Axial T2-weighted fastspin-echo ¡mage shows gross extracapsular tumoral Involvement of the 
extraprostatlc tissue (arrows). B, The photograph of pathologic specimen shows close match for 
the status of the capsule and tumor volume (arrows). 
Table 2. Results of MR Imaging for capsular 
penetration with all histologic lesions 
Table 3. Results of MR imaging for capsular 
penetration with matched lesions 
MR Findings 
Present 
Absent 
Total 
Histopathology 
Present Absent 
6 5 
8 33 
14 38 
Total 
11 
41 
52 
MR Findings 
Present 
Absent 
Total 
Histopathology 
Present Absent 
6 4 
5 19 
11 23 
Total 
10 
24 
34 
Note: Sensitivity = 42%, specificity = 87%, 
accuracy = 75%, positive predictive value : 
55%. 
Note: Sensitivity = 55%, specificity = 85%, 
accuracy = 74%, positive predictive value = 
60%. 
capsular penetration occured in MR examinations with poor image quality due 
to motion artifacts. 
Histologically, seven patients had capsular penetration with a width of more 
than 5 mm; MR imaging correctly identified the capsular penetration in four of 
them. Seven patients had capsular penetration with a width less than 5 mm; MR 
imaging correctly identified two of them. Histologically, capsular penetration 
extended less than 1 mm into the periprostatic adipose tissue in seven lesions, 
1—3 mm, in six; and more than 3mm, in 1 patient (Fig. 4). Sensitivity of MR for 
depicting capsular penetration into the periprostatic tissue was respectively 14% 
when that penetration was less than 1 mm, 67% when 1-3 mm, and 100%. when 
more than 3 mm (Fig. 5). 
The capsular bulge sign was not used because it may lead to false-positive find-
ings [9]. Capsular bulge was found in four cases, once in a true-positive T2 tumor, 
once in a false-negative T3 tumor and twice in (for other reason) true-positive T3 
tumors. Thus this criterium would not change the overall accuracy for capsular 
penetration. 
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Fig 5. Bar graphs shows the relation of detecting capsular penetration with MR imaging {open 
bar), to the depth of tumor invasion (mm) on histopathology (solid bar). Sensitivity was 14%, 70% 
and 100%. for capsular penetration of less than 1 mm, between 1 and 3 mm, and more than 
3mm, respectively. 
Table 4. Results of MR imaging for seminal 
vesicle invasion 
Table 5. Results of MR imaging for seminal 
vesicle invasion for each patient 
MRI 
Present 
Absent 
Total 
Histopathology 
Present Absent 
4 7 
7 51 
11 57 
Total 
11 
57 
68 
MR Findings 
Present 
Absent 
Total 
Histopathology 
Present Absent 
3 5 
6 20 
9 25 
Total 
8 
26 
34 
Note: Sensitivity = 36%, specificity = 88%, 
accuracy = 79%, positive predictive value -
36%. 
Note: Sensitivity = 33%, specificity = 80%, 
accuracy = 68%, positive predictive value = 
38%. 
Five patients had also positive surgical margins. However, because the surgeon 
incised the capsule, capsular penetration could not be evaluated in those 
sections. (Overall figures are given in Tables 2 and 3). 
Invasion of seminal vesicles 
All 68 seminal vesicles were visualized. MR imaging showed tumor invasion in 11 
seminal vesicles of eight patients, of which four lesions were confirmed on histo­
pathology. In 51 out of 57 seminal vesicles, invasion was correctly excluded with 
MR imaging. The sensitivity was 36% (4/11). The specificity was 88% (51/57). 
The positive predictive value was 36% (4/11). The results are presented in Table 
4 and 5. The seven false-positive seminal vesicles showed no abnormalities in the 
corresponding histopathologic sections. In particular, fibrosis, inflammatory 
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Fig 6. Axial T2-weighted fastspin-echo image Fig 7. Axial T2-weighted fastspin-echo image 
of a 67-year-old patient shows thickening of of a 63-year-old patient shows more pronoun-
the wall of the seminal vesicles [arrows), ced tubular thickening (arrows) is demonstra-
Seminal vesicle invasion was confirmed at ted in this patient, but seminal vesicle Invasion 
pathologic examination. was not present at pathologic examination. 
Table 6. Results of detecting extra prostatic 
disease (T3) 
Histopathology 
MR Findings p < T 2 p > T 3 Total 
m < T 2 15 4 19 
m > T3 7 8 15 
Total 22 12 34 
Note: Sensitivity T3 = 67%, specificity T3 = 68%, 
accuray = 68%, negative predicting value T3 
= 79%, positive predicting value T3 = 53%. 
infiltrate, amyloid depositions and blood were excluded. Eight vesicles showed 
focal thickening of the tubular wall. Only four of them were true positive (Figs. 
6 and 7). 
Staging prostate cancer 
For all patients, we evaluated final staging of prostate cancer by comparing MR 
images with pathologic appearances (Table 1). With the TNM classification, stag­
ing was correct in 15outof34 (34%) patients. When staging was limited to depict 
locally advanced disease, (S: T3, formerly Jewitt stage C) sensitivity, specificity, 
accuracy and positive predictive values of MR staging were 67%, 68%, 68%, and 
5.3%, respectively (Table 6). 
One patient who had stage pT3b (bilateral capsular penetration) disease was 
staged with MR imaging as mT3c without capsular perforation. Another patient 
was correctly staged as mT3 because of a false-positive and a false-negative lesion; 
thus staging by MR imaging in these patients was correct for an incorrect reason. 
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Discussion 
Motion artifacts were the primary cause of low-quality images in five examinations 
(14%). Also, of these five cases, three had false-positive capsular penetration. 
Little is reported in the literature about significant motion artifacts and the use 
of ERC. However, with FSE imaging and a pelvic phased-array multicoil, one 
study reported significant motion artifacts in up to 45% of examinations when 
glucagon was not used versus 7% with glucagon [8]. 
Number and localization 
In our study, we achieved good correlation between number and localization of 
tumors. The positive predictive value and sensitivity level was relatively high, 
comparable to that of other studies [12, 14, 25, 28]. We confirmed that tumors 
located ventrally and centrally on histopathologic examination are pitfalls for 
false-negative tumors. Carter et al. [28] found a sensitivity of 15% in detecting 
anterior tumors, a percentage considerably lower than they achieved in detecting 
posterior tumors (85%). Outwater et al. [12] did not identify any of 29 central 
gland tumors, and 41 of 56 (73%) of peripheral tumors on MR imaging that used 
an ERC technique. 
Causes for false-positive findings that are reported in the literature include 
hyperplasia, prostatitis, postbiopsy hemorrahge with blood in the extracellular 
methaemaglobin state, and areas of cystic change [25]. Cystic change increases 
the signal intensity of the peripheral zone, resulting in a relatively low signal 
intensity compared with adjacent areas of normal prostate which may be 
confused with malignant lesions. We found histologic evidence of hematoma nor 
other pathologic changes in areas defined as haematoma on Tl-weighted images. 
These findings concur with a study in which 27 false-positive lesions that corres-
ponded with areas of hemorrhage on Tl-weighted images did not show any 
pathologic substrate, especially no evidence of hemorrhage [14]. Also the 
pathologist, cited by Tempany et al., stated that the effects of hemorrhage and 
biopsy are difficult to quantify and cannot always be identified at pathologic 
analysis [16]. 
Tumor volume 
Tumor volume is a known predictor of pathologic stage [17]. With a tumor 
volume larger than 12 cc, extraprostatic spread of disease has likely occurred, 
whereas tumors smaller than 4 cc are usually locally confined [20]. Tumor 
volume is reported to correlate more closely with progression than with capsular 
penetration [19]. 
We found a poor correlation between tumor volumes calculated from MR im-
ages and those found at pathologic examination. Although pathologic examina-
tion frequently showed tumor extension into the central and ventral part of the 
prostate, MR images overestimated mean volume in all lesions and in matched 
lesions. We could not identify any reasons for this overestimate of tumor volume 
by MR imaging. 
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Studies performed with MR imaging using body coils reported a poor correl­
ation between tumor volume as depicted on MR imaging and the volume 
calculated from the pathologic specimen [5, 21, 22, 24]. No studies in the 
literature used an ERC, although one study was performed with an external array 
coil and FSE technique [25]. This study reported a significant correlation be­
tween tumor volume calculated with MR images and that of the pathological 
specimen (R=0.81, P<0.001), but their accuracy was not enough to be helpful in 
making clinical decisions. 
To meet the problems of low predictive values for detecting tumors and 
estimating their volumes, studies have been performed that evaluated Г contrast 
medium enhanced Tl-weighted images [ 11,29]. However improvement over T2-
weighted FSE images was not observed. Nonetheless, the report of one study that 
used dynamic, single-slice Tl-weighted technique after Г contrast medium with 
a high-time resolution (one image/sec) suggests that a better delineation of pros­
tate cancer detection, volume, and staging may be possible with MR imaging [30]. 
Capsular penetration 
Accuracy for capsular penetration in our study was low for matched lesions 
(55%) because capsular penetration was less than 3 mm in all but one case. On 
matched lesions we found no relation between the width or length of the capsule 
at pathologic examination and the staging accuracy with MR imaging. Five 
patients with positive surgical margins due to incission by the surgeon through 
the capsule were classified as T2 because penetration through the prostatic 
capsule could not be confirmed. Of these five, MR classification was T2 in three 
and T3 in two cases. 
In a recent overview, Schriebler et al. stated that body coil MR imaging proves 
unsatisfactory at detecting capsular penetration due to the limited spatial 
resolution of the imaging technique [31]. MR imaging that uses ERC technique 
is reported to provide a more reliable identification of the prostatic capsule [15]. 
Detection of capsular penetration with MR imaging with ERC technique had a 
sensitivity of 67% compared with body coil MR imaging that had a sensitivity of 
44% in the same patient cohort. However results of recent studies of MR imaging 
with ERC technique showed limited accuracy for detecting capsular penetration 
[9, 12, 14, 16]. For example, Tempany et al. reported accuracy rates of MR imag­
ing with ERC technique for detecting capsular penetration from different 
institutions ranged from 33% to 54%, less accurate compared to conventional 
body-coil MR imaging [16]. 
These conflicting findings may result from the lack of highly specific and sen­
sitive diagnostic criteria for capsular penetration. One study has evaluated six 
different diagnostic criteria for capsular penetration [ 12]. The positive predictive 
value of each individual sign ranged from a minimum of 4% for capsular thicken­
ing to a maximum of 34% for extracapsular tumor. 
It should be noted that focal penetration probably has a prognosis comparable 
to T2 tumors [3]. Therefore, only identification of deeper penetration may be of 
clinical importance [32]. 
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Seminal vesicle invasion 
The accuracy for detecting seminal vesicle involvement in our series agreed with 
that in other series. A high specificity (85%-97%) and a low sensitivity (21%-63%) 
[9, 14, 16] were reported. In our study, the figures were 82% and 50%, respect-
ively. Although we could not explain the false-positive findings in the histo-
pathology, low signal intensity of the seminal vesicles on T2-weighted images can 
be caused by amyloid deposits [33], or seminal vesicles that contains stones or 
blood [31]. Focal tubular thickening proved unreliable in predicting seminal 
vesicle involvement in our series. 
Overall staging 
In our study, staging according to the TNM classification was correct in 47% of 
the patients. Accuracy for differentiating a T2 from a T3 tumor was 68%. Except 
for Hricak et al. [14] other studies restricted staging to differentiating T2 from 
T3. The first series on imaging with an ERC reported a 82% accuracy rate which 
was a 16% improvement over body coil staging with the same cohort of patients 
[ 15]. Recent series reported an overall accuracy of 54%-68% for MR imaging that 
used an ERC [9,12,14,16]. It must be noted that the accuracy in prospective stu-
dies (51%) is considerable lower than in retrospective studies (67%) [14, 34]. 
The patient group in our study was limited to the patients who underwent rad-
ical prostatectomy. It should be emphasized that we also perform MR imaging on 
the prostates of patients who did not underwent radical prostatectomy for 
reasons of positive lymph nodes, or because of the overall staging results. The 
accuracy rate might well be different if this group was also included 
Difficulties in evaluating the literature 
The continuous, rapid technical development of image sequences and coil 
design like pelvic phased-array and integrated endorectal pelvic phased-array 
coils [35] can produce a wide divergence of image quality. Imaging with the 
combination of an ERC and a phased-array multicoil is now advocated as the 
most powerfull imaging tool. 
In addition, a broad spectrum of diagnostic signs (often indirect) and 
differently defined criteria for capsular penetration make meta-analysis of the 
literature difficult. For example, authors of one report changed image 
sequences, surface coils, and diagnostic criteria during the study [14]. Also, not 
all reports are blinded in the same way. Accuracy levels may be pushed higher 
when clinical data (PSA, prior histories of prostatitis, and locations of the positive 
biopsy findings) are integrated with interpretation of the images as recommen-
ded by Schiebler et al. [31]. Furthermore it is often difficult to assess the extent 
that information gained from MR imaging was used in patient management 
(verification bias) [36,37]. In our institution, the prevalence of T3 tumors at 
operation has decreased from 63% in the study byjager et al. [10] to 35% in this 
study. Because prostate cancer often leads to surgery at an early stage [38], cor-
rection for verification bias remains impossible. For these reasons, comparison 
of our presented figures to those of other studies is very difficult. 
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Conclusion 
Although MR imaging using an ERC with FSE was n o t highly accurate in piedict-
ìng definitive tumor volume or definitive stage, the technique may prove helpful 
when selecting patients for definitive therapy because small capsular penetration 
of less than 1 m m often not detected by MR-imaging, does not rule out radical 
prostatectomy Follow-up studies are neccessary to evaluate the effect of under-
staging minimal capsular penetrat ion 
In our series, overstaging occurred frequently in cases with low quality image 
due, at least in a part, to motion artifacts 
Because tumor volume is hkely to be more impor tant than focal capsular 
penetrat ion, the accuracy of assessing tumor volume must improve Dynamic, 
single-slice Tl-weighted technique that uses an Г contrast medium with high-
time resolution (1 image/sec) shows promise of improved accuracy [30] 
Because the value of MR imaging is not yet established a n d because the results 
of studies are difficult to compare, we conclude that those who perform MR ima­
ging in cases of prostatic cancer should d e t e r m i n e their own standard of accu­
racy by carefully compar ing their imaging results with histopathologic findings 
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Interlude I 
Amyloidosis of the Seminal Vesicles 
Simulating Tumor Invasion of Prostatic 
Carcinoma on Endorectal MR Images 
G. Jager1, E. Ruijter2·3, J. de la Rosette2, С. van de Каа3 
Departments of Radiology, 2Urology and 3Pathology, University Hospital Nijmegen, 
The Netherlands 
Abstract 
Amyloid deposits within the seminal vesicles are a common finding at autopsy. 
The incidence increases with age. Amyloid deposits can mimic tumor extension 
into the seminal vesicles due to prostate or bladder cancer on T2-weighled 
Magnetic Resonance (MR) images. We describe a case of seminal vesicle amyloi­
dosis demonstrating the MR appearance and the characteristic pathologic find­
ings. Recognizing seminal vesicle amyloidosis may prevent overstaging prostate 
cancer on MR images. 
Introduction 
Amyloid deposits within the seminal vesicles are a common finding at autopsy. 
The reported incidence ranged from 9-16% [1,2] in an unselected population of 
men over the age of 50. The incidence increased with age and was found in 21 % 
of men over 75 year [2]. Despite the high incidence, only two reports in the 
radiologic literature have described the Magnetic Resonance (MR) appearance 
of seminal vesicle amyloidosis [3,4]. In both cases, amyloid deposits were 
misinterpreted as tumor extension into the seminal vesicles due to prostate or 
bladder cancer. With the increasing use of MR as a staging modality, more men 
with vesícula amyloidosis will undergo such an examination. Recognizing this 
entity may prevent overstaging the tumor. We describe a patient in whom seminal 
vesicle amyloidosis was misinterpreted as extension of prostate cancer into the 
seminal vesicles on MR images obtained with an endorectal coil. 
Case Report 
A 61-year old, previously healthy man was referred to the urologie department 
because of a palpable nodus in the right lobe of the prostate. Transrectal ultra-
sound examination demonstrated a hypoechoic region in the base of the 
prostate extending into both seminal vesicles. Biopsies revealed bilateral mode-
rately differentiated adenocarcinoma of the prostate. MR images were obtained 
with a 1,5 Τ Siemens SP system (Siemens, Erlangen, Germany), using a Medrad® 
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(Pittsburgh, PA, USA) endorectal coil by using a 26 cm field of view, 5-mm sec­
tion thickness, 1-mm intersection gap, with a 512 χ 216 matrix. Axial TI (TR 420 / 
ТЕ 22) and axial, sagittal and coronal FSE T2-weighted images TR 2940, TE 160, 
13 echotrains) were performed. 
The T2-weighted demonstrated an area of low signal intensity bilaterally in the 
base of the prostate (fig la,b,c). This was interpreted as prostate cancer 
extendeding into the base of both seminal vesicles. Because radical surgery is not 
the treatment of choice in patients with seminal vesicle invasion, additional ultra­
sound guided needle biopsies of the prostatoseminal vesicular junction were 
obtained. One of the three cores demonstrated moderately differentiated adeno­
carcinoma. Seminal vesicle epithelum was not present. One core showed small 
eosinophilic deposits at the end of the biopsy. In retrospect, this deposit was amy­
loid material. Because seminal vesicle invasion could no be confirmed with these 
biopsies, radical prostatectomy was thought to be the best treatment. 
Following radical prostatectomy, the specimen was fixed with formalin and 
embedded in paraffin. Four-micron thick tissue sections were stained with hema-
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Fig 1. D. Histopathologically 
specimen (1 OOx) at the level of 
the ejaculatory ducts. Hugh 
amounts of amyloid are easily 
recognized as amorph eosin-
ophilic material, that shows a 
characteristic apple-green 
birifrigence in polarized light 
after staining with Congo red. 
toxylin and eosin. The specimen showed moderately differentiated bilateral 
adenocarcinoma of the base of the prostate. The tumor volume was 2.0 cc. 
Because routine stains showed amorphic eosinophilic material in the wall of the 
seminal vesicles suspect for amyloidosis, additional staining with Congo-red was 
performed. The deposits showed a positive staining reaction with apple-green 
birefrigence in polarized light characteristic of amyloid (fig Id). The amyloid 
deposits were found exclusively around the collecting ducts of the seminal 
vesicles in the base of the prostate and in the muscular layer of both seminal 
vesicles. Tumor invasion into the seminal vesicles was excluded histologically. 
Discussion 
The appearance of normal seminal vesicles is a grape-like configuration with a 
homogeneous hyperintense content on T2-weighted MR images. The most 
important MR criterion for tumor invasion into the seminal vesicle is an 
abnormal low signal intensity within the lumen of the seminal vesicle [5]. Focal 
thickening of the wall of the seminal vesicle is also considered a criterion for 
seminal vesicle invasion [6]. The accuracy for detecting seminal vesicle involve-
ment on endorectal coil images varies. A high specificity (85-97%) and a low 
sensitivity (21%-63%) [7-9] have been reported. An explanation for false-positive 
seminal vesicle invasion by cancer may be biopsy-related haemorrhage [10]. 
However, this can be diagnosed on Tl-weighted images because of the high 
signal intensity of the hemorrhagic breakdown products. False-positive findings 
may also be due to chronic inflammation, and history of pelvic irradiation [11]. 
Finally, low signal intensity of the seminal vesicles on T2-weighted images may be 
the result of stones in the lumen of the seminal vesicles. 
Deposits of amyloid in the seminal vesicles as the cause of false-positive find-
ings on MR images has only been described in two reports. Kaj et al. [4] reported 
a patient with a noninvasive bladder carcinoma in whom seminal vesicle amyloid-
osis was misinterpreted as tumor extension into the seminal vesicles, resulting in 
an unnecessary cystectomy. Ramchandani et al. [3] described a patient in whom 
seminal vesicle amyloidosis was interpreted as metastatic extension of prostate 
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cancer on MR images obtained with an endorectal coil In this case the correct 
diagnosis was m a d e with ultrasound-guided needle biopsies 
Amyloid deposits in the seminal vesicles (localized senile amyloidosis) is con­
sidered a localized disorder Considering the high frequency of prostatitis and 
the local nature of amyloidosis these two entities may be related The disorder is 
rarely associated with systemic AA amyloidosis Histopathologically amyloid is 
easily recognized as a m o r p h eosinophilic material, that shows a characteristic 
apple-green b infngence in polarized light after staining with Congo red (fig Id) 
Both seminal vesicles are usually symmetrically involved [2] 
As in the previously reported cases, the low signal intensity of the seminal 
vesicles in the repoi ted case was caused by narrowing of the lumen and thic ken-
m g of the wall of the seminal vesicles due to amyloid deposits The radiologic 
appearance may be indistinguishable from that of tumor It is suggested that 
gadolinium may be helpful in making the diagnosis because amyloid does not 
e n h a n c e , whereas tumor invasion shows e n h a n c e m e n t [4J 
Because false-positive results may deny potentially curable patients an operat­
ion, MR imaging cannot have a high percentage of false positive results 
Considering the high incidence of seminal vesicle amyloidosis, the diagnosis of 
tumor invasion in the seminal vesicles should be confirmed with additional ultra­
sound-guided biopsies Radiologist, urologist and pathologist should be familiar 
with this disorder to suggest the right diagnosis 
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Carcinoma: MR Imaging with a Three-
dimensional T1 -weighted Magnetization 
Prepared-rapid Gradient-echo Sequence 
G. Jager1, J. Barentsz1, G. Oosterhof2, J. Witjes2, J. Ruijs1 
Departments of 'Radiology and ?Urology, University Hospital Nijmegen, 
The Netherlands 
Abstract 
Objective 
The purpose of this study was to evaluate a magnetization-prepared rapid gradi-
ent-echo (MP-RAGE) sequence as a three-dimensional (3D) Tl-weighted MR 
imaging technique to reveal lymph node metastases from carcinoma of bladder 
and prostate. 
Subjects and Methods 
Using a 3D Tl-weighted MP-RAGE sequence, MR images of 134 consecutive 
patients with prostate carcinoma (n=63) or urinary bladder carcinoma (n=71) 
who were scheduled for radical prostectomy or radical cystectomy were correl-
ated with histopathologic findings after fine-needle aspiration biopsy (FNAB) 
(n=6), open or laparoscopic pelvic lymph node dissection (PLND) (n=127), or 
autopsy (n=l). MR imaging was used 10 times to guide FNAB in 9 patients. 
Results 
The sensitivity, specificity, accuracy, and positive predictive value of the technique 
were 75%, 98%, 90%, and 94%, respectively. Thin slice (1.2-mm) multiplanar 
reconstructed images correctly revealed pathological nodes in 33 patients. 
However, MR failed to reveal microscopic metastatic deposits in normally sized 
nodes in 11 patients. Two other patients had enlarged nodes without metastasis. 
Furthermore, MR-guided FNAB revealed metastases in six patients of nine 
patients, but failed to do so in the other three patients. 
Conclusions 
MR imaging with a 3D MP-RAGE sequence was accurate in revealing nodal 
metastases from carcinoma of the prostate and bladder. Therefore this imaging 
technique can be used to select patients for MR-guided biopsy or laparoscopic 
PLND. 
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Introduction 
The purpose of this study is to evaluate the diagnostic accuracy of using a three-
dimensional (3D) magnetization-prepared rapid gradient-echo (MP-RAGE) MR 
technique for staging regional lymph nodes in patients with prostate or bladder 
carcinoma. 
Subjects and Methods 
One hundred and thirty-four consecutive patients with biopsy proven prostate 
carcinoma (n = 63, mean age 64, years 48-73) or invasive urinary bladder 
carcinoma (n=71, 55 males, 16 females, mean age 59 years, range 38-75) were 
considered suitable candidates for curative surgery on basis of clinical stage, local 
and regional MR staging, and their general condition. 
In patients with prostate carcinoma, clinical stage was based on digital rectal 
examination, transrectal ultrasound, PSA (mean 8.2 range 2.4—40) and histologic 
tumor grade (9 good, 42 moderately, and 12 poorly differentiated). All patients 
with bladder cancer had biopsy proven muscle invasion. Nine patients had 
moderately, and 64 patients had poorly differentiated tumors. 
MR imaging was done using 1.5-T magnet (Magnetom 63/48 SP/4000; 
Siemens, Erlangen, Germany) and a Helmholt/ double surface coil. To reduce 
bowel motion, patients received 0.5 mg of glucagon IV before the examination. 
To reduce respiratory motion, an adjustable belt was wrapped around the 
abdomen producing slight abdominal compression. In the 3D MP-RAGE imple­
mentation that was used, Tl weighting was obtained by means of a 180° inversion 
pulse for magnitude preparation. For each of the phase-encoding steps in the 
second dimension, the inversion preparation was applied and then the rapid 
gradient-echo data acquisition was carried out; the latter step extended into the 
phase encoding for the third dimension. The sequence parameters were: 
10/4/500 (TR/TE/inversion time); flip angle, 10°; matrix size, 192 χ 256; field 
of view (FOV), 25 cm; two acquisitions; and voxel size, 1.0 χ 1.3 χ 1.6 mm. A total 
of 128 contiguous images were obtained in 9 min. From this image set, off-line 
multiplanar reconstruction of images in specific planes were performed depend­
ing on the preference of the investigator. A plane parallel to the external iliac 
vessels was always included. In patients with bladder carcinoma the 3D-MP-RAGE 
sequence was part of local staging [1], in patients with prostate carcinoma the 
sequence preceded local staging with an endorectal surface coil. Image inter­
pretation was done by two experienced investigators who were unaware of the 
clinical and surgical findings except that the patient was a candidate for prostat­
ectomy or cystectomy. The image quality was assessed good or poor as described 
before [1]. The investigators performed multiplanar reconstructions of the MP-
RAGE data in what they considered to be the optimal plane. In the first 40 
patients, all reconstructions were done independently by both investigators. 
Later, as the study proceeded, the prostate and bladder carcinoma reconstruc­
tions were each done by a single reader. When in doubt, independent double 
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Fig. 1. Lymph node metastases in a 54-year-old patient with T3b bladder carcinoma. Recon-
structed three-dimensional magnetization prepared-rapid gradient echo image in plane parallel 
to right external iliac vessel A, and in a slightly angulated coronal plane B, reveals enlarged lymph 
node (arrow) along course of iliac vessels (diameter, 12 mm). Histology following fine-needle 
aspiration biopsy revealed metastatic deposits. 
Fig. 2. 65-year-old men with localized prosta-
te cancer and iliac metastases. Reconstructed 
three-dimensional magnetization prepared-
rapid gradient echo image in a plane parallel to 
the right external iliac vessel reveals a round 
obturator node with a diameter of 9.3 mm 
(arrow). Histology following laparoscopic 
lymph node dissection revealed metastatic 
deposit. 
reading was performed. Consensus was achieved in all cases. In de termining sizes 
of lymph nodes, maximal long axis and minimal axial measurements were 
obtained. The minimal axial size was defined in a plane perpendicular to the 
long axis through the thickest part of the node . From these measurements an 
index was calculated: the shortest axial size was divided by the long axis. Lymph 
nodes were considered pathological when the minimal axial diameter was 10 mm 
or more (Fig. 1) or when the minimal axial diameter was between 8 mm and 10 
mm and the index exceeded 0.8 (a round node) (Fig 2). The signal intensity of 
lymph nodes was not considered diagnostic for nodal metastases [2]. 
In nine patients, MR-guided biopsies of suspected enlarged nodes with a 18-
gauge MR compatible needle (Löfkin; Medicor, Türkenfield, Germany) . In one 
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Fig. 3. 57-year-old man with bladder carcinoma and lymph node metastases. Fast reconstruc­
ted three-dimensional magnetization prepared-rapid gradient echo image reconstructions in 
transversal A, and multiple angulated plane B, obtained during fine-needle aspiration biopsy. 
Needle tip (arrow) and lymph node (arrow head) are visible. Phase wrap of patient's wrist is visi­
ble within the left gluteal muscle. 
patient, the procedure was repeated after an inconclusive result. To determine 
the ideal percutaneous approach, multiple angulated images were reconstructed. 
T h e position of the needle tip was checked with a transaxial and sagital two-
dimensional spin echo scan with these: 200/15 (TR/ТЕ); matrix size, 192 χ 256; 
FOV, 25 cm, and contiguous slice thickness, 5mm. We also used a fast 3D MP-
RAGE sequence with these parameters: 10/4/500 (TR/TE/inversion time); flip 
angle, 10°; FOV, 25 cm, matrix size, 128 χ 256 (Fig. 3). T h e procedure took 30-60 
minutes and was d o n e on outpatients. 
T h e MR findings were compared with histopathologic findings after FNAB in 
six, o p e n or laparoscopic PLND in 127, and autopsy in one patient. 
Results 
Overall 
Lymph nodes with an axial diameter of 3 m m could be visualised (Fig. 4). Initi­
ally, multiplanar reconstructions were per formed in 20 min: after a learning 
curve, we did them in 10 min. Results of nodal staging are presented in Tables 1 
and 2. 
MR imaging revealed lymph n o d e metastases in 33 of 44 patients. MR imaging 
failed to depict metastases in 11 patients with non-enlarged nodes. No metastatic 
disease was found in two patients with enlarged nodes. 
T h e MR technique proved to have a sensitivity of 77%, a specificity of 94%, an 
accuracy of 98%, and a positive predictive value of 95%. 
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Fig. 4. 52-year-old man with prostate cancer. Reconstructed three-dimensional magnetization 
prepared-rapid gradient echo image 3D MP-RAGE reconstructions in coronal A, and plane 
parallel to the right external iliac vessel B. Small lymph nodes (arrows) with a diameter of 3mm 
can be depicted along course of vessels. Histology following open lymph node dissection revea­
led no metastatic deposits. 
Table 1 . Results of pelvic lymph node staging in patients with prostate carcinoma 
Pathology 
MR imaging 
Results 
No metastases 
Metastases 
Totals 
No Metastases 
47 
1 
48 
Metastases 
6 
0 
15 
Totals 
53 
1С) 
63 
The MR technique proved to have a sensitivity of 60%, a specificity of 98%, an accuracy of 
89%, a positive predictive value of 90%, and a negative predictive value of 89%. 
Table 2. Results of pelvic lymph node staging in patients with bladder carcinoma 
Pathology 
imaging 
Results 
No metastases 
Metastases 
Totals 
No Metastases 
41 
1 
42 
Metastases 
5 
24 
29 
Totals 
46 
25 
71 
The MR technique proved to have a sensitivity of 83%, a specificity of 98%, an accuracy of 
92%, a positive predictive value of 96%, and a negative predictive value of 89%. 
Prostate carcinoma 
The MR pelvic lymph node findings in 63 patients with prostate carcinoma is 
correlated with pathological examination in Table 1. Metastases were revealed 
correctly in nine patients. In these patients, 15 enlarged lymph nodes were shown 
with a mean diameter of 11 mm (range, 8-18 mm). In three of these patients 
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Fig. 5. 58-year-old man with prostate cancer and a false-negative node at MR examination. Re-
constructed three-dimensional magnetization prepared-rapid gradient echo image MR images 
in coronal A and plane parallel to right external iliac vessel B. Lymph node with a diameter of 6.2 
mm is visible (arrow). This node contained metastatic deposits at pathologic examination. 
lymph node metastases were present in round nodes with a diameter of 8 or 9 
mm. In six patients, lymph node metastases were present in normal sized nodes. 
The diameter of the largest false-negative node was 6.2 mm (Fig. 5). In the one 
patient with a false-positive lymph node, we measured a diameter of 9.5 mm on 
reconstructed MR images. 
Bladder carcinoma 
The MR pelvic lymph node findings in 71 patients with invasive bladder carc-
inoma is correlated with pathological examination in tahle 2. Metastases were 
predicted correctly in 24 patients. In these 24 patients 39 enlarged lymph nodes 
were detected. The mean axial diameter was 12 mm (range, 8.5-18 mm). 
Metastases in five patients were predicted correctly because of the round shape 
of those metastases. The diameter of the involved nodes was 8.5-9.5 mm. In one 
patient with false-positive nodes, the minimal axial diameter of the largest node 
measured 15 mm. However, this node did not contain metastatic disease. 
In nine patients with enlarged nodes, MR imaging was used to guide FNAB. 
All patients appeared to have metastases. In four patients, insufficient aspirated 
material precluded diagnosis. These cases were classified as false-negative. In one 
of these patients the procedure was repeated with sufficient material aspirated 
for diagnosis. In six patients tumor cells could be demonstrated following MR-
guided FNAB. All failures occurred in the first five procedures, suggestive a 
"learning curve" for this procedure. 
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Discussion 
Nodal staging accuracy of MR imaging 
Evaluation of local and regional lymph nodes is done in patients who are can­
didates for radical prostatectomy or cystectomy. The finding of lymph node meta­
stases obviates surgery. 
Surgical pelvic lymph node dissection (PLND) is the most invasive and reliable 
method establishing the presence of metastatic disease in pelvic lymph nodes. 
However, frozen section has been reported to be false negative in 33% of patients 
[3]. Laparoscopic PLND is less invasive and almost as accurate in sampling lymph 
nodes (90%). However, this method requires more skill and experience and if no 
lymph nodes metastases are found a second operation is necessary [4]. 
Computed tomography (CT) and magnetic resonance (MR) are reported to 
be the most accurate non-invasive techniques for nodal staging. Reported accura­
cies rates obtained from literature show a wide range. For CT the sensitivity varies 
from 0% to 100%, and the specificity varies from 44% to 100% [5,6]. For MR the 
sensitivity varies from 0% to 100% and the specificity varies from 94% to 100% 
[7-9]. Compared with CT, MR has better soft tissue contrast and the potential of 
multiplanar imaging without the use of Г contrast. MR imaging may therefore 
be potentially more accurate than CT scanning, but currently both imaging 
methods are considered similar in their ability to facilitate nodal staging [2,5]. 
However, the most optimistic results were obtained with routine axial imaging 
with CT [6]. The CT technique proved to have a sensitivity of 78%, a specificity 
of 97%, and an accuracy of 94%. 
MR imaging is considered superior in local staging of prostate carcinoma [10] 
and slightly better in local staging of bladder carcinoma [1,2]. Because we use 
MR imaging for local staging in patients with prostate and bladder cancer we 
investigated if MR imaging is appropriate in nodal staging. Then local and nodal 
staging can be done in one session. 
On the other hand, CT provides the opportunity to do fine-needle aspiration 
biopsy (FNAB) more easily [6]. FNAB is a minimal invasive method to determine 
lymph node metastases histologically. The mean reported sensitivity of FNAB is 
70% [5]. 
We investigated the value of a 3D MR technique in evaluating the presence of 
nodal metastases in patients with prostate or bladder carcinoma. Because we 
obtained thin slices in multiple directions, the minimal axial diameter could be 
determined correctly. The multiplanar reconstruction allowed us to evaluate the 
nodal shape. By defining the maximal normal size for a round node as 8 mm 
instead of 1 cm, the number of true-positives increased from 25 to 33 and there 
was one more false-positive. These Findings concur with a study of Vinicombe et 
al. [11] who suggest a lower limit of normal size for pelvic lymph nodes. They 
suggested 7 mm for internal iliac, 8 mm for obturator, 9 mm for external iliac 
locations and 10 mm for external iliac locations. Oyen et al. [6] also suggest lower 
limits of normal size lymph node. They consider every asymmetrical lymph node 
with a diameter of 6 mm or more abnormal. Retrospectively, we had adapted 6 
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mm as the upper size limit of normal, 18 patients with normal lymph nodes 
would have been judged pathological (false-positives) and in one patient with a 
true-positive node of 6.2 mm would have been correctly classified (Fig 3). For this 
reason we chose 8 mm as the upper limits of normal size pelvic lymph nodes. 
Reconstructions in every desired plane prevented us from over-estimating the 
size of the node which can result from measuring the node in a plane not 
perpendicular to the long axis. This may explain the relatively low number of 
false-positive lymph nodes in our series. 
Nodal staging in prostate carcinoma 
The presence of lymph node metastases in patients with prostate carcinoma is 
highly related to tumor grade and clinical stage. The chance of a patient, with a 
well differentiated Tla tumor having lymph node metastases is zero [12,13], 
whereas a patient with a poorly differentiated T3 tumor has a reported proba-
bility of having nodal metastases between 68% [14] and 93% [12]. Lymph node 
metastases can also be assessed by prostate specific antigen (PSA) level [13,15]. 
Because of an increasing trend to perform surgery on patients with earlier 
stage prostate carcinoma, the incidence of positive lymph nodes has decreased 
to 5%-15% [16]. Therefore, routine use of PLND is no longer considered just-
ified in all patients [13]. Also, the diagnostic yield from imaging in nodal staging 
is considered too low for routine use [13]. Cost-effective analysis carried out by 
Wolf et al. [5] pointed out that imaging should be restricted to patients with a 
high probability of having lymph node metastasis. They stated that when the 
probability of positive nodes, based on PSA, grade and clinical stage, was 32% the 
sensitivity of the imaging method should be 36% to be beneficial, when the sens-
itivity was 25% as in their series prior probability should be 45%. On condition 
that FNAB was performed with a sensitivity of 70%. 
We achieved a high sensitivity in our series of patients. Because metastases may 
occur in normally sized nodes the sensitivity of imaging cannot be 100%. In a 
series of 39 lymph node metastases, 14 metastases were present in lymph nodes 
even smaller than 1 mm! Of these, seven were not recognised at frozen section 
[3]. 
One has to keep in mind that the study subjects are restricted to those patients 
whose true disease status is verified by pathological examination (verification 
bias). For example if the confidence of clinicians in MR-staging increases, the 
need for pathological confirmation decreases. A patients with obvious T3c 
disease (seminal vesicle invasion) and enlarged lymph nodes will no longer 
undergo FNAB. Therefore the number of true-positive nodes becomes lower. In 
addition the real prevalence of disease has effect on the reported figures. For 
example, in our hospital MR staging is no longer indicated in patients with low-
grade tumors, who have a PSA concentration lower 10 ng/ml. For this reason we 
expect a lower number of true-negative results. 
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Nodal staging in bladder carcinoma 
The presence of lymph node metastases is related strongly with tumor stage. 
Lymph node metastases in patients with superficial tumors (less than T3) are rare 
but, if the deep muscle layer is involved (T3A), or if there is extravesicular 
invasion the incidence of lymph node metastases rises to 20-30%, and 50-60%, 
respectively [17]. Although some authors advocate radical cystectomy even when 
the patient has microscopic metastases [18], radical cystectomy is not justified if 
lymph node metastases are detected [19]. 
The sensitivity of nodal staging in patients with bladder carcinoma was better 
than in patients with prostate carcinoma. The difference between these two 
groups of patients is also present in the compilation of results obtained from the 
literature. For prostate cancer and for bladder cancer the overall reported 
sensitivity for nodal staging with MR imaging is 32% [5,7,8,10,20-25] and 64% 
[9,19,26-32], respectively. 
The 3D MP-RAGE sequence in our hospital an integral part of bladder carc-
inoma staging. Therefore, nodal staging does not affect the costs of staging. 
In patients with bladder carcinoma laparoscopic PLND is no longer done 
because of the chances of tumor seeding. In patients with positive lymph node 
on MR imaging we have now started doing MR-guided FNAB. 
Fine needle aspiration biopsy 
FNAB of pelvic lymph nodes has been performed under sonography [33], CT 
[6], or lymphangiography [34] guidance. The reported sensitivity varies from 
50% to 100% with an average of 70% [5 ]. In this preliminary study of MR-guided 
FNAB, we achieved a sensitivity of 60% in 10 procedures, obviating the need for 
radical cystectomy in six of nine patients. False-negative results were obtained in 
the first patients done. Compared with CT, MR-guided FNAB has no advantages, 
it is more time-consuming and more expensive. With the development of new 
open-configurating, superconducting MR imagers, which allow direct access to 
the patient during the procedure [35], and MR compatible puncture devices, we 
expect some of these problems will be overcome. 
Conclusion 
Nodal staging using the 3D MP-RAGE technique is excellent compared to other 
MR studies and to most CT studies. Therefore, local and nodal staging should be 
integrated in one MR examination. We advise MR staging in all patients with 
bladder carcinoma with muscular invasion who are considered surgical can-
didates and in candidates for radical prostatectomy who have biopsy Gleason 
score of S 7 (moderately and poorly differentiated tumors) and PSA concentra-
tion S: 10 ng/ml. If a lymph node is considered positive a fine needle biopsy is 
advised. 
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Interlude II 
Sensitivity of Frozen Section Examination of 
Pelvic Lymph Nodes for Metastatic Prostate 
Carcinoma 
G.Jager 
Letter to the Author 
I read with particular interest the article of Davis [1] about the sensitivity of 
frozen section examination of pelvic lymph nodes for metastatic carcinoma. The 
section in which the results are of frozen section are compared with imaging 
techniques found in MEDLARS literature research deserves comment. 
The conclusion of the author that "...Frozen section analysis ... is more sen­
sitive for the diagnosis of prostate carcinoma in pelvic lymph nodes than is MRI 
because more than half of the metastases are smaller than the 1,0-cm resolution 
limit of the MRI", may be misleading and is not correct 
The upper limit of the spatial resolution of Magnetic Resonance Imaging 
(MRI) and Computed Tomography (CT) is much smaller than 1 cm. It depends 
on many factors such as field of view, matrix size, slice thickness, image quality 
(signal-to-noise ratio, motion artifacts) and contrast between the object and sur­
rounding structures. Using a three-dimensional imaging technique we achieved 
an in-plane resolution of 1.3 χ 1.0 mm and were able to visualize lymph nodes 
with a diameter of 4 mm [2]. 
Also the literature search on imaging techniques is incomplete. The reviewed 
number of articles on CT and MRI is far too low, e.g the review does not obtain 
the article of Rifkin et al. [3] which includes more patients (185) investigated 
with MRI than the compilated data of the articles cited by the author. 
In general, it is believed that MRI is equal to CT for lymph node imaging. The 
advantage of CT over MRI is that fine needle aspiration of a nodal mass may be 
more easy to perform. In contrast to lymphangiography where metastases are 
visible as filling defects of 4 mm or more [4], MRI and CT do not allow direct 
visualization of lymph node metastases. The main criteria to assess the presence 
of lymph node metastases is the axial diameter of the lymph node. Perhaps the 
author confused "resolutions limit" with what is considered as the upper limit of 
normal sized lymph node. However, criteria for positive lymph nodes are 
arbitrary. In the cited articles the upper border of normal varies from 1.0 cm 
[5,6] to 1.5 cm [7,8]. There is a general tendency to lower the upper limit of 
normal. Recently, Vinnicombe et al. [9], who found only 2% of normal lymph 
nodes have a short axis diameter of more than 1 cm, suggested that the sensitivity 
of CT in depicting lymph nodes may be improved by adopting lower limits of 
normal. These may become 7 mm for internal iliac, 8 mm for obturator, 9 mm 
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for common iliac and 10 m m for external iliac nodes. Using a 3-dimensional 
imaging technique we could add the shape of the node in the judgement ; r o u n d 
nodes with a diameter of 8 m m and an index of 0,8 (shortest axial d iameter 
divided by the long axis) or less were considered abnormal . With these criteria 
the figures for sensitivity, specificity and accuracy were 58%, 96%, and 9 2 % (will 
be presented at the 81th annual meet ing of the Radiologic Society of Nor th 
America). Van Poppel et al. [10] consider even nodes of 6 mm on CT positive. 
Calculated figures for sensitivity, specificity a n d accuracy were 77,8%, 96,6%, and 
93,7%. When fine needle aspiration biopsy was per formed to evaluate suspected 
nodes the calculated figures were 77,8%, 100% and 96,5%. These figures are 
unique and may be not representative for imaging in general. 
However, the argument that frozen section is more sensitive than CT or MRI 
does not implicate that there is n o place for imaging as is suggested in the 
abstract and on page 665. Nodal metastases detected by imaging will considerably 
save financial costs, morbidity, hospital stay, and patients discomfort. However, 
only 10% of patients who are candidates for surgical cure have metastatic nodal 
disease [11,12]. Therefor cross-sectional imaging is not indicated for all patients. 
It should be restricted for patient who are at high risk for having lymph n o d e 
metastases d e p e n d i n g on PSA, stage and the Gleason biopsy score. Wolf et al. 
[13] have estimated that when the sensitivity of imaging was 36% (baseline 
derived from li terature), imaging would be beneficial when the probability of 
metastases was 32% and when suspected lymph nodes will be confirmed by fine 
needle aspiration biopsy. 
In conclusion, imaging is still of value in a selected group of patients who are 
at high risk for nodal metastases to prevent them from an unnecessary operat ion. 
In my opinion, in this g roup of patients, the u p p e r limit of normal should be 
lower than 1 cm. 
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Author's Reply 
Gustave L Davis M D 
Department of Pathology and Laboratory Mediane 
Bridgeport Hospital 
Bridgeport 
I thank Dr Jager foi his comments He is correct regarding my confusion be-
tween the spatial resolution limit of the imaging technique and the criteria for 
metastasis (the axial diameter of the lvmph node) T h e purpose of my study was 
to assess the diagnostic efficiency of frozen section and then compare the results 
with the only other modality available for the direct assessment of lymphnode 
metastases prior to prostatectomy- imaging 
I did miss the 1990 article by Rifkin et al [1] which indicates that magnetic 
resonance imaging and computed tomography had high specificity (96%) but 
very low sensitivity (4%) for the diagnosis of lymph node metastases "because 
nei ther technique has the ability to ïdenüfy microscopic spread of disease [1]" 
In 1995, using either a 4-mm resolution limit lymphangiography or b-mm limit 
for computed tomography, the best imaging technique cited by Dr Jagei, 18 oí 
39 or 22 of 39 patients in my series still would no t have been detected due to the 
microscopic size of their metastases below these respective resolution limits 
Accepting Dr Jager 's criticism, I would change the conclusion of the paper to 
"Frozen section analysis is more sensitive for the diagnosis of piostate carcinoma 
in pelvic lymph nodes than are imaging techniques because 46% of the 
metastases in our series are smaller than the lowest (4 mm) resolution limit of 
the imaging techniques to be reported by Barentsz et al [2] " 
Imaging is of value in identifying patients who are at high risk for lymph node 
metastases to prevent them from an unnecessary operat ion [3] Regardless of 
imaging technique or user, with an upper limit of normal lower than 1 cm, half 
of our patients with metastases would still be missed and we are therefore unable 
to identify them in advance of lymphadenectomy 
The rapid changes taking place in both the diagnosis and treatment of 
prostate cancer are reflected in editorials and articles concerned with prostate 
specific antigen (PSA), biopsy grade, and t reatment variables in the literature 
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[3-8] concurrent with the submission and publication of my paper. Imagers face 
the same di lemma as surgeons; how to select patients who will benefit by use of 
a procedure. Strategies for detecting lymph n o d e metastases [7,8], including 
imaging with or without fine-needle aspiration of "positive" lymph n o d e meta­
stases and two-stage (open or laparoscopic) lymphadenectomy, a t tempt to pre­
select patients at risk for lymph n o d e metastases by means of PSA, biopsy grade, 
and clinical staging. 
Clan current clinical or laboratory parameters preselect patients who ai e at risk 
for lymph n o d e metastases? Using PSA levels a n d biopsy grade, we have been 
unable, retrospectively, to differentiate false-negative frozen-section patients 
(microscopic lymph n o d e disease) from true positive patients (unpublished 
data). Only at the extremes of PSA and grade can we predict lymph n o d e meta­
stases with greater efficiency than by frozen section and, for the majority of the 
patients, there is n o relation between PSA and biopsy grade, and size of the meta­
stasis. Metastasis do n o t necessarily result in lymph n o d e enlargement. 
As prostate cancer is diagnosed "earlier," I anticipate that a greater proport ion 
of metastases will be occult [9], for the diagnosis of which c u r r e n t routine clin­
ical laboratory tests a n d imaging are inadequate. T h e application of new 
diagnostic technology (such as polymerase chain reaction amplification [10] for 
detection of currently occult cancer cells in the blood stream or tissue obtained 
with minimally or noninvasive techniques with imaging localization) is n e e d e d 
for the accurate and cost-effective staging and t reatment of prostate cancer. 
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Abstract 
Purpose 
To assess the role of single-slice gadolinium enhanced dynamic subtracted (DS) 
magnetic resonance (MR) imaging in improvement of the accuracy of fast spin 
echo (FSE) endorectal coil (ERC) MR imaging in the staging and localizing of 
prostate cancer. 
Materials and Methods 
ERC MR imaging was performed in 57 patients with clinically localized prostatic 
carcinoma. ConventionalTl-weighted Spin-Echo (SE), Fast-Spin-Echo (FSE) T2-
weighted, single slice DS-Turbo-FLASH (TF) following bolus injection of 0.1 
mmol gadopentetate dimeglumine/kg body weight (time resolution one image 
every 1.2 or 2.4 seconds), and late post contrast Tl-weighted SE sequences were 
obtained. Retrospective interpretation of the MR images was performed blindly 
by two independent readers. Onset and steepest slope of enhancement were graded. 
Results were compared with the corresponding slice of the other sequences with 
respect to tumor involvement and capsular penetration. The findings were 
correlated with corresponding postoperative histopathologic section. 
Results 
As visualized on DS-TF images, prostate cancer was characterized by early and 
rapidly accelerating enhancement compared to surrounding tissues. Poorly 
differentiated tumors showed the earliest and greatest rate of enhancement. 
Sensitivity, specificity and accuracy to depict tumor involvement for the two 
readers were 74% and 73%, 79% and 83%, and 77% and 78%. On FSE MR 
images the sensitivity, specificity and accuracy to depict tumor involvement for 
the two readers were 57% and 58%, 88% and 82%, and 73% and 71%, respect­
ively. With DS-TF images, capsular penetration was better depicted for bolli rea­
ders in 6 and 9 patients respectively, but worse in 0 and 2 patients respectively. 
Overall staging was better in 5 and 7 patients. Tumor was better delineated in 7 
and 8 patients. 
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Conclusion 
Tumor was better depicted and delineated when DS-TF images were included 
than at routine ERC images, including late post-contrast images. Also staging 
results were better. 
Introduction 
MR imaging is considered to be an effective tool for staging of prostatic cancer 
[1 ]. However, it is also stated that the technique adds little to the traditional data 
based on information gained by clinical staging completed with information 
obtained from biopsies such as tumor grade, number and lengths of cores con­
taining malignancy, and involvement of seminal vesicles [2-4]. 
The use of gadopentetate dimeglumine (gadolinium-DTPA) to increase the 
diagnostic information of MR imaging, has been described in the literature 
[5-10]. The results suggest that post-contrast Tl-weighted images do not provide 
additional information compared with T2-weighted images, but that it may be 
useful in evaluating seminal vesicle invasion in equivocal cases [6,10]. Therefore, 
the use of gadolinium is not warranted for routine staging of prostatic cancer. 
Brown et al. [8] evaluated early phase Tl-wcighted bolus enhanced MR imaging 
for the evaluation of prostatic carcinoma. They found that information provided 
by Tl-weighted images during the early phase of contrast enhancement enables 
the best delineation of tumor within the gland. 
Experience with Dynamic Subtraction-Turbo FIASH (DS-TF) MR imaging in 
bladder and breast cancer indicated that malignant lesions demonstrate an 
earlier and faster enhancement compared to benign lesions [11,12]. The 
diagnostic value of fast dynamic contrast enhancement in prostate cancer has not 
been evaluated previously. The aim of the present study is to evaluate the 
complementary diagnostic value of single slice DS-TF MR imaging in patients 
with prostate cancer. 
Subjects and Methods 
Patients 
The patient population consisted of 57 patients with clinically localized prostate 
cancer who underwent DS-TF MR imaging complementary to the routine stag­
ing MR examination of the prostate. The examinations were performed between 
August 1993 and February 1996. Only patients who underwent radical prostat­
ectomy were included in this study. Patients who received hormonal treatment 
before surgery were excluded from this study. Patients mean age was 64 years 
(range 48-73). Biopsies preceded the MR imaging by an average of three weeks. 
Patients underwent radical prostatectomy within three weeks after imaging. All 
prostatectomies were performed on patients in whom no lymph node metastases 
were found on laparoscopic lymph node dissection prior to the operation or by 
frozen section examination during the operation. 
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MR Technique 
All images were obtained with a 1.5T Siemens Magnetom SP system (Siemens, 
Erlangen, Germany), using a Medrad® ERC (Medrad, Pittsburgh, PA). The coil 
was inserted with the patient in the lateral decubitus position and inflated with 
50-100 cc of air. Peristalsis was suppressed by Г administering 1 mg glucagon. A 
tight band was wrapped around the patients abdomen to decrease respiratory 
movement. 
First, a sagittal Tl-weighted localizing image was obtained to confirm coil 
positioning and to select locations for the axial images. Axial Tl-weighted ima­
ges (420/22[TR/ТЕ], two acquisitions) as well as axial, sagittal and coronal FSE 
T2-weighted images (2940/160[TR/TE], echo-train lengths of 13, three acqui­
sitions) were acquired. All examinations were performed using a 4- or 5-mm sec­
tion thickness with a 0.8-1.5 mm gap, 26-cm field of view, and a 512 χ 216 matrix. 
An equalizing processing after application and a filter algorithm to compensate 
for near-field effect were also used. We changed the phase encoding gradient to 
decrease motion artifacts over the prostate. 
The section for the gadolinium enhanced MR images was selected from the 
T2-weighted axial FSE images. A section was chosen in which tumor and normal 
prostatic tissue was likely to be present. When no tumor was visible a level 
demonstrating normal anatomic details or benign prostatic hyperplasia (BPH) 
was chosen. In this section during I.V. bolus injection of 0.1 mmol Gd-DTPA/kg 
body weight (Magnevist®; Schering, Berlin, Germany), 63 images using a single-
section turbo F1ASH (Fast Low Angle Shot) magnetization-prepared sequence 
were acquired (7/3/15 [TR/TE/TI], 10 flip angle, 128 χ 256 maüix, 200-mm 
FOV, 1 cm section thickness) with a speed of 1 image per 2.5 seconds in 15 
patients (two acquisitions) and a speed of 1 image per 1.25 seconds in the 
remaining 42 patients (one acquisition). Finally multi-slice axial late post con-
trast Tl-weighted SE images (420/22[TR/ТЕ], two acquisitions) were obtained. 
The dynamic single section images were transferred to a diagnostic HP work 
station. At our department a computer program was developed to subtract the 
TF images, and to calculate color coded time-, negative and positive slope, and 
maximal signal intensity images (Fig. 1) [11,12]*. In time-images, the beginning 
of enhancement of prostatic tissue in relation to the beginning of arterial enhan­
cement is color coded, and projected over the unenhanced image. The begin­
ning of enhancement was defined as an increase of 10 arbitrary units (A.U.) 
above the base noise line. In the positive slope-image the slope of maximal signal 
intensity increase is color coded. The negative slope image displays the wash-out 
of contrast material. The maximal signal intensity images display maximal 
enhancement 45 seconds after the beginning of arterial enhancement. Time-sig­
nal intensity curves were made in operator defined regions of interest (ROI) to 
determine enhancement patterns of iliac vessels and benign and malignant pro­
static tissue. 
Note: The subtraction technique is commercially available on most MR systems. The software 
program for time-, slope, and maximal signal intensity images is available from the authors on 
request. 
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Fig. 1. 63-year-old man with poorly differentiated tumor at the left side. 
A, FSE image, note small low-signal-intensity area in the peripheral zone at left side. 
B, Time-images demonstrate very early and rapid enhancement. 
C, negative slope image demonstrates a relative high wash out. 
D, T1 -weighted post-contrast image demonstrates a relative low signal intensity. 
Ε-G, subtracted images show early and rapid enhancement of the tumor. There is also some 
enhancement outside the contour of the prostate. This was interpreted as capsular perforation 
by one reader. 
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Fig. 1. H, Histopathologic specimen shows 
small poorly differentiated tumor at the right 
side (red), there was no capsular penetration. 
MR ¡mage evaluation 
The T2-weighted FSE, the Tl-weighted post-contrast and the subtracted images 
were interpreted independently by two observers investigators (G.J.J, and J.O.B.) 
who were blinded to clinical findings, laboratory and imaging results. 
The T2-wcighted, the Tl-weighted post-contrast images, and DS-TF images 
were interpreted for tumor presence, location, and capsular penetrat ion. At the 
level of the DS-TF images the prostate was divided into 4 areas: peripheral zone 
left and right and central zone left and right. The presence of tumor was scored 
on a five-point scale (1 = definitely absent, 2 = probably absent, 3 = indetermina-
te , 4 = probably present, Γ> = definitely present) . The presence of capsular pen­
etration was scored on a three-point scale (1 = no, 2 = indeterminate, 3 = yes). 
Regions representing cancer were outl ined in a diagram. 
On T2-weighted images, an area in the peripheral zone with a relatively low sig­
nal intensity zone was considered to represent malignancy. Low signal-intensity 
areas in the central zone were not interpreted as being malignant. If a low signal 
area intensity showed high signal on the corresponding Tl-weighted image, the 
area was considered to be haematoma. T h e criteria for capsular perforation 
were: disruption of the prostatic capsule, infiltration of the periprostatic fat, low-
signal-intensity stranding, and involvement of the neurovascular bundle . A bulge 
in the contour or capsular thickening was interpreted as "probably" (on the 
three-point scale = 2) capsular perforation [13]. 
T h e onset and slope of e n h a n c e m e n t were assessed on hard copies m a d e of 
the subtraction set. T h e onset of e n h a n c e m e n t in relation to the onset of arterial 
e n h a n c e m e n t was registered in seconds, the slope of e n h a n c e m e n t was scored 
on a three-point scale (1 = slow, 2 = normal, 3 = fast). 
On the subtracted images a lesion was considered to represent malignancy if 
the slope of e n h a n c e m e n t was faster and the onset was earlier relative to the 
adjacent prostatic tissue. E n h a n c e m e n t outside the contour of the prostate was 
considered to represent capsular penetrat ion (Fig 2.) 
Using these criteria the additional value of the turbo-FLASH technique was 
evaluated. 
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Fig 2. 63-year-old-man with tumor involvement on the right side. 
A, T2-weighted FSE image demonstrates retraction of capsule on the left side which was not 
interpreted as capsular penetration. B, DS-TF image shows enhancement outside the contour 
of the prostate. This appeared to be capsular penetration on final pathologic examination. 
Pathologic examination 
T h e prostatectomy specimens were in toto fixed overnight in a solution of 10% 
neutral buffered formalin. Step-sections were made at 4 m m intervals in a plane 
parallel to the base of the prostate, which corresponded to the slices used on axial 
MR imaging. After separating the step-sections into right and left halves, all sec­
tions were routinely e m b e d d e d in paraffin. Tissue sections of 4 μπα were prepared 
and stained with haematoxylin and eosin. Regions representing cancer were out­
lined on the glass cover a n d retraced onto a diagram of the axial histologic 
sections that extended from the base to the apex of the prostate. Measurements 
were multiplied by a factor 1.1 to correct for tissue shrinkage d u e to fixation. 
Data Analysis 
Analysis of the correlation of MR findings and histopathology were per formed 
by two radiologists (G.J.J., J.O.B.) and one pathologist (E.T.G.R). T h e MR ima­
ges were correlated with tumor maps based on the histopathologic sections. T h e 
level of the DS Turbo-FIASH images was determined by its location between the 
apex and base of the prostate. T h e corresponding slice of the tumor m a p was 
then adjusted. Because of the difference between slice thickness of the Turbo-
FIASH images (10 mm) compared to the FSE images and the pathologic exam­
ination (4 m m ) , tumor maps of adjacent slices were also considered. 
Penetrat ion through the capsule was compared for each quadrant. 
Statistical analysis 
T h e McNemar test (exact distribution) was used to evaluate the differences in 
assessing tumor presence and capsular penetrat ion by both techniques. 
Cohen ' s Kappa (к) analysis was used to test for agreement between both rea-
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ders with respect to the presence and absence of tumor and capsular penetra­
tion.(к <0.4() = poor;« >0.4,<0.75 = good;« >0.75 = strong). 
When sensitivity and specificity figures for tumor presence and for capsular 
penetration were calculated; score 4-5 and score 3, respectively were considered 
present. 
Additional diagnostic value 
The overall additional diagnostic value of DS-TF images to routine MR imaging 
was determined as follows: major improvement of the diagnostic performance 
was present when DS-TF correctly depicted up or down staging (T2->T3, T3-
>T2), minor improvement was present when the estimated area of tumor involve­
ment as determined on the DS-TF images became within the 25% range of the 
actual tumor(Fig 3 and 4). Diagnostic performance was defined worse (major) 
when DS-TF depicted incorrectly up or down staging, and worse (minor) when 
the estimated area of tumor involvement as determined on the DS-TF images, 
exceeded the 25% range of the actual tumor area correlated with the corre­
sponding step section histology slice. Additional information of DS-TF images 
that did not change the final staging result was called minor. For example, DS-
TF depicted capsular penetration not depicted on FSE images, but FSE already-
depicted seminal vesicle invasion (T3c). 
Results 
Correlating MR images with histopathologic findings 
The correlation between MR images and the corresponding histopathologic sect­
ion was difficult in most patients. The most caudal section of MR images was 0.5-
1.5 centimeter more distal than the most apical section of the prostatectomy 
specimen. Also the angle by which the sections were cut in both techniques was 
never exactly the same for either technique (difference, 5°-15°). Furthermore, 
the shape of the prostate changed after surgery and fixation, compared with the 
shape of the gland within the body at the time of imaging. Also making correl­
ation difficult was the fact that prostate tumors are very irregular and often dem­
onstrate fingerlike projection with ill defined margins that did not display on MR 
images of 4 or 5 or 10 millimeters (whereas the histologic sections were only 4 
μιτι thick). We tried to overcome these problems using tumor maps, which gave 
a good three-dimensional picture of the prostate and were of help in assessing 
the corresponding level. 
Characterizing enhancement patterns 
Differences in enhancement within the prostate were best visible in the early 
phase of the first pass of gadolinium. However, most glandular tissue of the 
prostate displayed early enhancement and there was a considerable variation be-
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Fig 3. 66-year-old-man with prostate cancer. 
A, T2-weighted FSE ¡mage demonstrate low signal intensity on the left side and bulging of the 
contour. B,C,D, Subtracted, time and slope image show late and slow enhancement. No tumor 
was found at final pathologic examination. 
tween the start of enhancement of the external iliac artery (t = 0) and the start 
of enhancement of prostatic tissue. Therefore, the onset of enhancement was 
judged relative to the adjacent prostatic tissue. We were also not able to charac-
terize the signal intensity-time curve (slope of enhancement) for malignant or 
benign lesions. Therefore relative differences in slope values in the selected slice 
were used to differentiate between benign and malignant lesions. 
Interobserver agreement 
Interobserver agreement for the interpretation of MR images with and without 
DS-turbo-FLASH was strong. Cohen's Kappa was respectively 0.79 and 0.78. 
Both observers agreed that non-dynamic Tl-weighted post contrast images did 
not provide additional information compared with T2-weighted FSE images. 
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Fig 4. 57-year-old-man with prostate cancer. 
A, T2-weighted FSE ¡mage demonstrate small low signal Intensity on the left side 
B,C,D, Subtracted, time and slope image show early and rapid enhancement of the peripheral 
zone. At final pathologic examination tumor location was almost symmetrically bilateral, corre-
sponding with the area of rapid enhancement. 
E, Photograph of histopathologic section (haematoxylin and eosin stain; magnification 20x) 
shows moderately differentiated tumor on both sides. 
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Detection of tumor 
Л total of 228 quadrants were identified, rated and analyzed. Tumor was present 
in 102. The results for predicting tumor presence with and without DS-TF ima­
ges are presented in Table 1. The sensitivity was 57% and 58% for FSE images 
and 74% and 73% for DS-TF images, respectively (P = not significant). The 
specificity was 88% and 82% for FSE images and 79% and 83% for DS Turbo-
FIASII images, respectively (P = not significant). The accuracy was 73% and 71 % 
for FSE images and 77% and 78% forbs Turbo-FLASH images respectively (P = 
not significant). 
Tumor volume 
In 17 (30%) and 18 (32%) patients the area of tumor involvement estimated with 
FSE images fell within a 25% range of the actual area of tumor involvement, 
respectively. With DS Turbo-FLASH images the estimated tumor volume fell 
within a 25% range in 23 (40%) and 25 ( 44%) patients (P not significant). 
Capsular penetration 
In 19 different quadrants capsulai penetration was present at histopathologic 
examination in 14 patients. In the remaining two hundred and nine quadrants, 
capsular penetration was absent, including one site where capsular penetration 
could not be evaluated because the surgeon incised the capsule. FSE images 
correctly depicted capsular penetration in 4 and 3 quadrants, respectively. There 
were two false-positive sites. DS-TF images correctly depicted capsular penetra­
tion in 9 and 10 quadrants, respectively. With DS-TF there were one and two false-
positive quadrants. Therefore capsular penetration was predicted more accur-
Table 1 . Sensitivity and specificity for tumor localization for FSE and DS-TF images 
pathology 
tumor present 
PZ (n=72) 
CZ (n=30) 
total (n=102) 
pathology 
tumor absent 
PZ (42) 
CZ (84) 
total (126) 
sensitivity for tumor localization 
Routine 
Reader I Reader II 
74%(53) 
17%(5) 
57%(58) 
76%(55) 
13%(4) 
58%(59) 
specificity for tumor localization 
routine 
64%(27) 
98%(82) 
88%(109) 
52%(22) 
96%(81) 
82%(103) 
DS-TF 
Reader I 
81%(58) 
57%(17) 
74%(75) 
DS-TF 
57%(24) 
90%(76) 
79%(100) 
Reader II 
83%(60) 
47%(14) 
73%(74) 
74%(31) 
87%(73) 
83%(104) 
Note: Numbers are in parentheses PZ = peripheral zone, CZ = Central zone. The accuracy 
was 73% and 71 % for FSE images and 77% and 78% for DS Turbo-FLASH images respect­
ively (P = not significant). 
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Table 2. Additional diagnostic value of dynamic subtracted turbo-FLASH images. 
Diagnostic Performance Observer (I) Observer (II) 
with DS Turbo-FLASH 
Better (major) 5 8 
Better (minor) 13 12 
Equal 34 30 
Worse (minor) 5 6 
Worse (major) 0 1 
Note. Diagnostic performance was defined better (major) when DS-TF images correctly depic­
ted up or down staging (Τ2->Τ3, T3->T2), and worse (major) when DS-TF incorrectly depicted 
up or down staging in addition to complete routine imaging. Minor improvement or deterioration 
was defined when the estimated area of tumor involvement of the selected slice became, res­
pectively within or out the 25% range of the actual tumor area, or when depicted capsular pene­
tration did not change final stage. 
ately by DS-TF by both readers in 6 and 9 quadrants in 6 (11%) and 9 (16%) of 
patients respectively, but less accurately in respectively 0 and 2 quadrants in 2 
(4%) of the patients (P = not significant). Three other patients had capsular 
penetration at a different level than DS-TF images. Capsular penetration was 
depicted in one of these three at FSE images. 
Tumor grade 
Ten patients had poorly differentiated tumors. All were recognized by DS-TF. 
Five of these showed the most steepest enhancement from all lesions, and the 
earliest (within one image) (Fig. 1 ). These numbers however, were too small for 
statistical analysis. There were no differences in enhancement between good and 
moderately differentiated tumors. 
Additional diagnostic value 
The overall additional diagnostic value of DS-TF images to routine MR imaging 
is summarized in Table 2. We achieved overall major improvement in 5 and 7 
patients respectively, and overall minor improvement 8 and 6 patients respect­
ively. 
Discussion 
The merit of MR imaging is in the local staging of prostate cancer. Although 
microscopic capsular penetration may not be demonstrated on T2-weighted ima­
ges, MR may be helpful in selecting patients with a potential resectable disease 
[404,307]. blowever, more accurate staging is needed. 
Several studies have addressed the use of contrast material in MR imaging of 
the prostate [148,48,151,344,405,376,345]. In the normal prostate the central 
zone enhances more than the peripheral zone. Both enhance homogeneously. 
In the presence of BPH, the enhancement pattern of the central gland is marked-
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ly inhomogeneous [48,344]. BPH may occasionally arise within the peripheral 
zone of the prostate leading to an inhomogeneous enhancement. 
Prostate cancer is frequently reported to show increased enhancement -
compared to adjacent glandular tissue, especially in die peripheral zone; in the 
central zone the difference is less obvious [344]. 
Reported studies suggest that contrast enhancement in prostate cancer is of 
limited value and may be only helpful in cases of seminal vesicle invasion 
[48,345]. 
Brown et al. [344] evaluated bolus enhanced MR imaging in prostatic carc­
inoma. They showed that early phase contrast enhanced images enables best the 
definition of tumor within the gland in 50% of patients and demonstrated caps­
ular spread more clearly in 80% of the patients. In that study no pathologic 
correlation could be obtained. 
We evaluated the enhancement of the prostate cancer during the first pass of 
contrast with fast dynamic imaging with a temporal resolution of one image per 
1.2 or 2.4 seconds following Г bolus administration of contrast. 
Malignant breast, bladder and bone tissue have demonstrated early and fast 
enhancement. The enhancement pattern can be characterize by the onset of 
enhancement [169,146], or by the slope of enhancement [162]. Our findings 
indicate that prostate cancer also enhances early and that differences in enhance­
ment are visible in the early phase of the first pass. However, due to a large 
variation in the onset and slope of enhancement among patients and minor 
differences between the onset of enhancement of carcinoma and benign tissue, 
we were not able to define a cut-off time nor a slope value to differentiate benign 
from malignant prostatic tissue. Therefore, the onset and slope of enhancement 
were judged relative to adjacent prostatic tissue. 
Because we used subjective signs, independent double reading was performed 
to test for inter-observer variability. There appeared to be strong agreement be­
tween both readers for the interpretation of both FSE and DS-TF images. This in 
contrast to other studies which reported high inter-observer variation in est­
imating tumor location, volume and capsular penetration of the prostate 
[56,171 ]. The high agreement of our readers may be due to the study design. The 
slice of the DS turbo-FLASH images was chosen in a plane that was likely to con­
sist both cancer and normal tissue on the T2-weighted FSE image. 
Reported figures for detecting tumors with MR imaging are in general poor 
especially for central gland tumors [90,68]. With DS-TF the sensitivity for 
localization of tumors was consistently better than with FSE images. It was con­
firmed that tumors located ventrally and centrally on histopathologic examina­
tion were easily missed on T2-weighted images. With DS-TF there were 12 and 10 
more true-positive centrally located tumors but also 6 and 8 more false-positive 
tumors. 
Tumor volume is a predictor of pathologic stage [116]. Except for one study 
performed with an external array coil [54], studies performed with ERC coil 
[404] and body coil MR imaging reported a poor correlation between MR tumor 
volume and the volume as calculated from the pathologic specimen 
[61,67,43,55]. Studies evaluating post contrast Tl-weighted images also reported 
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Fig 5. 52-year-old-man with very small focus 
of prostate cancer (0,4cc). 
A and B, Time and maximal signal intensity 
images show symmetrically rapid and early 
enhancement. 
C, Pathologic specimen of the corresponding 
section show BPH. No tumor was present. 
poor correlation between the estimated and calculated volume [48]. Brown et al. 
[345] found better correlation during the early phase of enhancement but in this 
study pathologic confirmation was not obtained. 
Compared to FSE images, DS-TF images estimated the area of tumor involve-
ment better in 10-12% of the patients. However, in only 30%-32% of patients the 
area of tumor involvement estimated with FSE images fell within a 25% range of 
the actual area of tumor involvement. One reason for overestimating tumor 
volume on DS-TF images was rapid enhancement of BPH in the central zone 
(Fig. 5). This error can be avoided when symmetrical central enhancement is not 
considered as cancer. In an overview, Schiebler et al. [109] stated that body coil 
MR imaging gives unsatisfactory results in detecting capsular penetration. The 
detection of capsular penetration improved with ERC MR (sensitivity 67%) 
compared to body coil MR (sensitivity 44%) in the same patient cohort [58]. 
Results of recent studies with ERC MR, however, showed a limited accuracy for 
detecting capsular penetration as low as 33% [114,173,148,171,404]. 
In the present study the sensitivity for capsular penetration was 21% and 16% 
with FSE, and 47% and 53% with DS-TF, respectively. These figures appeared not 
to be statistical significant. The low sensitivity for capsular penetration with FSE 
is due, at least for a part, to the fact that we only studied one level, preferably in 
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which capsular penetration was not obvious. False-positive results on DS-TF ima­
ges may be due to enhancement of a capsular artery. The vessel may be differen­
tiated from tumor by a different enhancement curve (Fig. 1). 
T2-weighted MR images do not provide information about tumor grade, 
another predictor of clinical outcome. A noteworthy finding of the present study 
was that DS-TF depicted all poorly differentiated tumors and that five of them 
showed the earliest and fastest enhancement of all lesions. These numbers are 
however too small for statistical analysis. These findings seems to be in contradic­
tion with the findings of Yoshi/.ako et al. [405], who reported that poorly diffe­
rentiated tumors demonstrated less enhancement on contrast-enhanced Tl-
weighted images compared to moderately differentiated tumors. However, we 
also observed that rapid enhancing tumors demonstrated relatively low signal 
intensity on late post-contrast images (Fig. ID) which may be explained by the 
high wash-out of contrast material from the tumor (Fig. 1С ). 
Our study demonstrates that the results of MR imaging with DS-TF were con­
sistently better than routine MR imaging although routine use of single slice DS-
TF images did not significantly improve tumor localization and staging results. 
The results of the DS-TF may however, be improved. In the first place there was 
a learning curve. Secondly, a number of examinations was carried out in patients 
in whom clinical stage was obvious from FSE images. In these cases DS-TF ima­
ges did not provide additional information. Thirdly, the single slice imaging tech­
nique we used only allows evaluation in one plane. Better delineation of tumor 
and tumor volume may become possible, when with echo-planar imaging a dy­
namic multi-slice technique can be performed with a time resolution of minimal 
3 seconds. Also the spatial resolution is considerable less than with FSE images 
and the slice is twice as thick. Another limiting factor of our technique was the 
ERC dependent variation of signal intensity throughout the prostate gland. 
Especially lesions located ventrally are difficult to recognize because they show 
relative less enhancement. This problem may be overcome with the introduction 
of a combined endorectal phased array coil. Also easily applicable corrections for 
the coil profile may be helpful. 
Conclusion 
This study demonstrates that prostate cancer shows early and rapid enhancement 
and that with fast imaging and the use of a subtraction technique tumor assess­
ment can be improved. Further improvement of the technique however, may be 
achieved by application of a multislice sequence and by correction for the sen­
sitivity profile of the ERC throughout the prostate gland. 
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Abstract 
This report describes the use of an endorectal coil and a double spin-echo pulse 
sequence for localized Ή MR spectroscopy of the normal prostate in volunteers. 
The spectra showed well-resolved signals for citrate, (phospho) choline and 
creatine protons. Additional signals were assigned to taurine and myo-inositol 
protons. J-modulation of the main and outer peaks of citrate could be monitored 
in vivo. Apparent relaxation times T, and T2 have been estimated for the methyl 
protons of cholines and creatine. An effective T, relaxation time was estimated 
for the main peaks of the citrate multiplet. Ratios of the integrals of these reso­
nances have been evaluated and tissue contents of choline and creatine were 
estimated using the H 2 0 signal as an internal reference. 
Spectroscopic imaging experiments revealed a lower relative citrate signal in 
central parts of the prostate than in peripheral parts. 
Keywords: human prostate, magnetic resonance spectroscopy, metabolites, 
spectroscopic imaging. 
Introduction 
Proton magnetic resonance spectroscopy ('H MRS) has been mostly applied to 
the brain in human studies. To extend its use to other parts of the human body 
seems less trivial. Problems involved in abdominal application of'H MRS are rela­
ted to the deep location and movement of some tissues of interest. Furthermore, 
dominating triglyceride signals, either from the target tissue itself or from ad­
jacent adipose tissue, often obscure resonances of relevant metabolites. 
With the advent of endorectal RF coils [1,2], the potential of Ή MR of the 
human prostate has improved substantially and several groups have explored the 
use of such coils to obtain Ή MR spectra of the human prostate [3-5]. The most 
prominent metabolite signal in these spectra is that of citrate, a compound 
abundantly present in the healthy prostate. The tissue content of citrate has been 
reported as a potential marker for prostate pathology, in particular to discrimin­
ate between the presence of adenocarcinomas and benign prostate hyperplasia 
(BPH) [6-13]. The intensity of the methyl proton signal of (phospho) cholines in 
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'H MR spectra of the prostate may also serve this purpose [5,12,13]. Localized 
'H MRS of the human prostate based on magnet field gradient techniques has 
been initiated employing the STEAM (Stimulated Echo Acquisition Method) 
sequence [4,9,13] and the PRESS (Point Resolved Spectroscopy) sequence [5,14]. 
In this paper we report on the application of a double spin-echo (or PRESS) 
sequence [15,16] in combination with endorectal coils in 'H MRS of the prostate 
of healthy volunteers. At an echo time of 135 ms well-resolved spectra were 
obtained showing major signals for citrate, choline compounds and creatine. 
Minimal contamination of these spectra with broad components facilitated the 
quantitation of metabolite levels. Furthermore, high quality Ή MR spectra were 
obtained in multiple locations of the human prostate by extending PRESS 
volume localization with phase-encoding gradients to collect a spectroscopic 
imaging data set. 
Materials and Methods 
Volunteers 
This study was approved by the local ethical committee. After informed consent 
was given 12 volunteers participated in this study. Of these volunteers 8 were 
examined with single volume localization, of which 3 were investigated twice. 
Four were examined in studies employing spectroscopic imaging. The ages of the 
volunteers ranged from 25 to 46. None of the volunteers had a history of genito­
urinary disease or showed any signs of clinical prostate disease. MR images 
obtained of the prostates were interpreted as being normal. The volunteers were 
examined in the supine position. A belt was applied around the lower abdomen 
with slight compression to reduce respiratory motion. No antiperistaltic drugs 
were used. 
MR Imaging 
MR examinations were performed on a 1.5 Τ MR system (Magnetom SP, 
Siemens, Erlangen, Germany) employing a body radio-frequency coil for excita­
tion. For MR signal reception a disposable endorectal probe (MEDRAD®, 
Pittsburg, USA) holding a surface coil with approximate length of 75 mm and 
width of 35 mm, was inserted. The probe was inflated with 50-100 ml of air to 
ensure tight positioning of the coil adjacent to the prostate. To visualize the 
prostate multiple slice MR imaging was performed in 3 orthogonal planes 
employing a turbo spin-echo (TSE) sequence (slice thickness: 5 mm, 1 mm 
interslice distance, field-of-view: 260 mm, matrix: 260*512, acquisitions: 2, Te: 
160 ms, Тг: 2940 ms). 
Single voxel MR spectroscopy 
Based on these images volumes were selected for localized Ή MRS employing a 
double spin-echo slice selective sequence (90o_T_180°_T_180°_(T-T)_Acquisition) 
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\vilh echo times (2T) between 30 and 270 ms. The delay time τ was 11 ms. The 
length of the sine-shaped RF pulses was 2.56 ms and the bandwidth of the 180° 
pulses was adjusted to select the same effective slice thickness as for the 90° pulse. 
The slice selective gradients were 2.67 mT/m, and EXORCYCLE phase cycling 
was applied. Field homogeneity was optimized for the selected volume using the 
resonance of water protons. For the detection of metabolite signals a chemical 
shift selective method [17] was used to suppress the water resonance and 2K data 
points were acquired with a spectral width of 1000 Hz. The nominal dimensions 
of the voxels were 1.5*1.5*1.5 cm (3.4 cc) except in two cases where voxels with 
nominal dimensions of 1.6*1.6*1.6 cm (4.1 cc) and 1.8*1.8*1.8 cm (5.8 cc) were 
selected. The scan repetition lime ranged from 1.6 to 4.5 s and the number of 
scans from 96 to 256. In addition a spectrum without water suppression was 
obtained for eddy current correction and for referencing purposes. 
To estimate apparent T^-relaxation times of metabolite proton spins in vivo, 
spectra were recorded at 4 different echo times between 65 and 270 ms. For the 
estimation of the apparent T2 relaxation time of water proton spins, 7 spectra 
were recorded without water resonance suppression at echo times between 30 
and 270 ms. 
Inversion recovery experiments to obtain apparent T¡ relaxation times were 
performed by the same pulse sequence used for localization, preceded by a non-
selective 180° inversion pulse (650 us). The echo time was 135 ms and the repe-
tition time 3 s. Five or six spectra were recorded at different delay times between 
the inversion pulse and the localization sequence ranging from 50 to 1000 ms. In 
the same way inversion recovery experiments were performed without water sup-
pression. The repetition time was set to 6 s and delay times ranged from 50 to 
2500 ms (number of delay times investigated 6-8). 
Besides these experiments with volunteers, inversion recovery experiments 
were also performed on a phantom (described below). Thirteen measurements 
were performed with inversion delay times between 40 and 1600 ms at a Tr of 6 s. 
Spectroscopic imaging (SI) 
In the SI experiments a transversal slice of 10 (or 11) mm thickness, 40 mm in 
the left-right and 30 mm in the anterior-posterior direction was selected for local-
ized 'H MRS by the double spin-echo sequence described above with an echo 
time of 135 ms. In these experiments τ was 14.5 ms, the pulse lengths were 5.12 
ms, the slice selection gradient in the z-direction 3 mT/m and in the other direc­
tions 1.4 mT/m. Gradients for phase encoding in two directions were applied 
during 1 ms in the τ period, to obtain a set of SI data within the preselected 
volume. The field-of-view was 160 mm. Data was encoded in a 16 * 16 matrix 
resulting in nominal voxels of about 1.0 cc. For the spectral dimension IK data 
points were acquired with a spectral width of 1 kHz. A total of 512 scans (2 scans 
per phase-encoding step) were acquired with a Tr of 1.6 sec resulting in an acqui­
sition time of 13.6 min. For eddy current correction and referencing purposes 
also an SI experiment without water suppression was performed. 
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Phantom 
To test the performance of MRS acquisition methods a phantom was used. It con­
sisted of a glass sphere with an outer diameter of 10 cm filled with a citrate solut­
ion prepared according to the average composition of expressed human 
prostatic fluid as reported by Kavanagh [18]. It contained 90 mM sodium citrate, 
8.8 mM ZnCl2, 16.7 mM MgCl2, 18.8 mM CaCl2, 63 mM KCl at pH 6.7. For refer­
encing and phasing purposes 13.6 mM glycine and 10 mM sodium acetate were 
added. The sphere was placed in a container filled with sunflower oil, to mimic 
the presence of periprostatic fat, which was positioned on the endorectal surface 
coil. 
Post-processing 
Post-processing of single volume measurements consisted of zerofilling to 4K 
data points and filtering as indicated in the figures. Eddy current correction was 
performed according to Klose [19] by a software procedure provided by the 
manufacturer. After this procedure usually only minor phase correction was 
necessary. 
In the case of spectroscopic imaging, post-processing consisted of Fourier 
transformation to spatial and frequency dimensions applying zerofilling to 2 К 
data points and a Gaussian filter for the frequency dimension. No k-space filter­
ing was used. Eddy current correction was performed as for the single voxel 
measurements. 
For fitting of signals in the frequency domain NMR1 software (New Methods 
Research, Inc., Syracuse, New York) was used. A p p a r e n t ^ and T 2 relaxation time 
values were derived by fitting the integrals of resonances to a single exponential 
function. 
Average values are presented with standard deviations (±SD). Chemical shifts 
are given in parts per million (ppm). 
Results 
Single volume measurements 
Spatial origin of spectra 
By histology the most simple subdivision of the prostate gland is in a central part 
(including transition /one tissue) and a peripheral part of which the latter part 
occupies about 70% of the normal prostate gland [20]. In order to minimize 
signal contributions of periprostatic triglycerides the volumes for MR spectro­
scopy in this study were located in the central part of the prostate mainly contai­
ning central zone / transition zone tissue. From inspection of the MR images the 
contribution of peripheral zone tissue to the selected volumes was estimated to 
be between 15 and 25% for nominal volumes of 3.4 cc. In two examinations, with 
nominal voxels of 4.1 and 5.8 cc the contribution of the peripheral zone to the 
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selected volume was estimated to be 30-40%. Because a part of the peripheral 
zone included in the voxels was closest to the endorectal surface coil, the actual 
contribution of signal intensity from this zone to the spectra will be somewhat lar­
ger. 
Homogeneity 
In the present volunteer studies we have encountered little problems with 
prostate movement. If tissue movement occurs, this usually becomes manifest 
during the shimming procedure. O n e examination failed due to bad shimming 
results. Shimming values of all other 10 single voxel examinations per formed at 
an echo time of 135 ms ranged from 3.5 to 10 Hz (full-width-half-maximum) with 
an average value of 6.2 ± 1 . 8 Hz. 
Assignment of spectral components 
Figure 1 shows a water resonance image of a transversal slice through the prostate 
of a volunteer also displaying the outl ine of the voxel selected for MR spectro­
scopy. T h e spectrum obtained from this voxel at an echo time of 135 ms is shown 
in Fig. 2. Assignments are indicated in the spectrum. These are based on previous 
high-resolution NMR studies of perchloric acid extracts of prostate specimens 
[12]. T h e most dominat ing metabolite resonance in the spectrum originates 
from citrate. At 1.5 Τ the 4 proton spins of citrate behave as a strongly coupled 
AB system with nearly identical chemical shifts showing 4 resonances of which 
the two central ones are most intense at the present experimental conditions 
[14]. In vivo usually only one peak is visible containing both these central com­
ponents. However, at shimming values of about 5 Hz (or less) the separate reso­
nance components of citrate start to get resolved (see below). In addition to citrate 
resonances all spectra showed peaks that could be assigned to the methyl protons 
of creatine and cholines. When referencing the creatine resonance to a chemical 
Fig. 1. Transversal MR ¡mage (T2-weighted) 
showing the prostate of a 28-year-old-volun-
teer. The volume selected for Ή MR spectros­
copy is indicated by a box. It has a nominal 
volume of 3.4 cc (1.5 * 1.5 * 1.5 cm). 
Fig. 2. Ή MR spectrum of the 
volume shown in fig. 1. This 
spectrum has been obtained 
with an echo time of 135 ms, 
a Tr of 1600 ms and 256 
scans. The half-width of the 
water resonance was 6 Hz 
Zerofillmg to 4K and a 
Gaussian filter (maximum at 
96 ms and half-width 148 ms) 
was applied to the FID before 
FT. No baseline correction 
was used. The indicated reso­
nance assignments are Ci for 
the central citrate compo­
nent, Cr for the methyl pro­
tons of creatine and Ch for 
the methyl protons of (phos-
pho-)cholme. 
shift position of 3.03 ppm, we find in spectra obtained at Te = 135 ms, an average 
position (n-10) for the choline peak at 3.21 ± 0.01 ppm, for the central position 
oí citrate at 2.63 ± 0.01 ppm and for the position of the water resonance at 4.68 
± 0.02 ppm. According to the extract studies the choline peak originates mainly 
from phosphocholine and choline compounds. Resonances of taurine, inositol, 
elhanolamine and polyamine protons may also contribute to signal intensity at 
3.20-3.25 ppm [12,13]. The spectrum in figure 2 shows very little contribution 
of triglyceride signals between 1.7 and 0.5 ppm. In some of the spectra signals in 
this region were more intense. These likely originate from periprostatic fat as 
verified by taking spectra of voxels located more to the periphery of the prostate 
which showed an increased intensity of these resonances. In the spectra with 
minimal triglyceride signals no indication for a signal of lactate was observed 
which should be visible as an inverted doublet at about 1.33 ppm at an echo time 
of 135 ms. 
At this echo time occasionally some additional weak resonances aie observable 
which we tentatively assign, on the basis of prostate extract studies [12], to pro-
tons of taurine (3.2-3.4 ppm), glutamate/glutamine (2.0-2.5 ppm) and inositol 
(3.54 ppm). These become better discernible at shorter echo times. See for 
instance the spectra in figure 3 obtained at echo times of 100 and 65 ms. At echo 
times between 65 and 100 ms it is still possible to obtain spectra with resolved 
resonances for citrate, cholines and creatine, but for spectra at Te below 65 ms 
resolution becomes worse and therefore these spectra are more difficult to 
analyse. Usually, there is more signal contribution of triglycerides between 1.7 
and 0.5 ppm at shorter echo times. 
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Fig. 3. MR spectra of the 
prostate of two volunteers 
obtained at different echo 
times. Nominal volumes were 
3.4 cc. Tr was 2000 ms. 
Processing was performed as 
for Fig. 2. Further details: 
Spectrum A. Te = 100 ms. 
Gaussian filter with maximum 
at 96 ms and half-width 160 
ms. Spectrum В. Te = 65 ms. 
Gaussian filter with maximum 
at 160 ms and half-width 160 
ms. 
In Ta 
Ch 
Cr 
Ci 
Glx 
= inositol 
= taurine 
= (phospho) choline 
= creatine 
= citrate 
= glutamine/ 
glutamate 
Fig. 4. MR spectra of the prostate of a volunteer obtained at different echo times. Nominal size 
of the selected volume was 5.8 cc. The Tr was 2000 ms. To aid visualization of the modulation 
of citrate resonances only the spectral part between 2.2 and 3.3 ppm is plotted. The multiplet of 
citrate is shaded grey. Echo times are indicated below the spectra. The same Gaussian filter was 
applied to all the spectra. 
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J modulation of the citrate signal m vivo 
At shimming values of about 5 Hz width for the water resonance at half height, 
occasionally it became possible to observe the small« outer signals of citrate at 
approximately 15-16 Hz from the central peaks Figure 4 shows the spectral 
region between 2 2 and 3 3 ppm with the citrate resonances at various echo times 
The outer peaks and the splitting of the main peak of citrate, at echo limes of 135 
ms and more, are well visible As described previously [14], the main citrate com-
ponent shows slow modulation at 1 5 T, both in vitro and in vivo In addition, the 
present data (see fig 4) show that the faster modulation of the outer peaks seen 
in vitro [14] also occurs in vivo At the present üming of the PRESS sequence the 
main citrate resonances have a relative maximal signal amplitude at an echo time 
of approximately 130 ms, while the amplitudes of the outer peaks are minimal 
[14,21] 
Apparent relaxation times 
In 3 volunteers we have been able to perform inversion recovery experiments to 
get an estimate of the effective Tj of the proton spins of some compounds In the 
localization scheme Te was set to 135 ms Figure 5 shows spectra of such an 
experiment Resonance integrals were determined by computer integration as 
described in the next secüon The mean effective T, obtained from these 
experiments was 339 ± 42 ms for the main component of the citrate signal com-
plex and 837 ± 89 and 864 ± 98 ms for the methyl protons of cholines and creat-
ine, respectively By the same procedure the mean effective T! of the water pro-
ton spins m the same volume elements of the 3 volunteers was 1481 ± 109 ms For 
comparison the effecüve T, value of the main resonance component of citrate in 
the phantom was also determined at Te = 135 ms This T, increases with 
temperature e g. al 22 °C a value of 360 ± 5 ms and at 32 °C a value of 534 ± 8 ms 
was found 
Apparent T, relaxation times of metabolite resonances were derived from 
PRESS locahsauon experiments with 4 different echo times (from 65 to 270 ms) 
as shown in fig 4 The mean values obtained for the choline and creatine signals 
were 227 ± 61 ms and 209 ± 97 ms respectively (n=3) To estimate the apparent 
T, of H^O spins 5 or 6 different echo times between 30 and 270 ms were used An 
average apparent T2 value of 98 ± 9 ms was found (n=4) To derive a ^-relaxa-
tion time for the citrate methylene proton spins is more difficult as its signals 
follow a complicated J modulation using a PRESS localization scheme [14,221 
The treatment of this problem for the interpretation of m vivo MR results will be 
the subject of a separate publication 
Quantitation 
The good resolution of the spectra obtained at an echo time of 135 ms allowed 
evaluation of the integrals of the resonances of cholines and creatine and of the 
main component of the citrate multiplet 
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Fig. 5. Spectra of an inversion recovery experiment of the prostate of a volunteer. The nominal 
size of the selected volume was 4.1 cc. The echo time was set to 135 ms, Tr to 3 s and 96 scans 
were accumulated for each spectrum The delay times (ms) between the inversion pulse and the 
first slice selective 90° pulse are indicated in the figure. Zerofilling to 4K and a Gaussian filter were 
applied. The same phasing was used for all spectra. These were plotted without baseline cor-
rection The inset shows the fit of the integrals of the main citrate resonances to a single expo-
nential function Cho = (phospho) choline, Cr = creatine, Citr = citrate. 
Integration of resonances in the frequency domain was performed in two 
different ways after Gaussian filtering and phasing. Gaussian filtering consisted 
of a 2 Hz Lorentzian line width removal and a 4 Hz Gaussian linewidth broad-
ening. Usually only minor baseline correction was needed. In the first approach 
signals were fitted to a Gaussian model function. In the second approach the 
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Fig. 6. Metabolite signal ratios of all single-
volume measurements performed at an echo 
time of 135 ms (•) The ratios were corrected 
for T, weighting (A)The volunteers at 29 and 
32 years of age have been measured at two 
different occasions For the 30 year old volun­
teer two similar measurements were per­
formed during the same examination separa­
ted in time by about 15 mm. 
A, Citrate / Choline ratio, B, Citrate / (Choline 
+ Creatine) ratio, C, Choline / Creatine ratio 
signal areas were obtained by computer integration. Integration of the main 
resonances of citrate was performed between the spectral limits of 2.49 and 2.77 
ppm, of the creatine methyl peak between 2.96 and 3.11 ppm, of the choline 
methyl peak between 3.12 and 3.30 ppm, and of the water resonance between 
4.42 and 4.94 ppm. The data were first evaluated as signal ratios. Since repetition 
times of the experiments varied between 1.6 and 4.5 s, the resonance integrals 
have been corrected with the effective T, values given above. Fig. 6 displays 
individual values, for the ratios of citrate and cholines, cholines and creatine, and 
citrate and the sum of cholines and creatine, as obtained by the signal fitting pro­
cedure. Note that the highest citrate ratios are observed for the two largest 
volumes measured. In the volunteer at 25 years of age a nominal voxel size of 5.8 
cc was measured and in the second measurement of the volunteer at 32 years a 
nominal voxel size of 4.1 cc was selected. The lowest citrate ratio was determined 
for the volume estimated to be the least contaminated with peripheral zone 
tissue: i.e. in the first measurement of the volunteer at 32 years of age. 
See Table 1 (column I) gives the average values of ratios obtained from all 
single voxel examinations at an echo time of 135 ms. The ratio calculations from 
computer integration of signals gave very similar results: i.e. citrate/choline, 
citrate/(choline + creatine) and choline/creatine were 2.10 ± 0.74, 1.47 ± 0.49 
and 2.44 ± 0.50, respectively. Column II gives the average ratios only including 
spectra from nominal volumes of 3.4 cc. 
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Fig. 7. A, Transversal MR ¡mage of the test 
phantom. At the same position an 11 mm thick 
slice was selected for spectroscopic imaging. 
The grid indicates voxels from which spectra 
have been acquired. The dashed line deline-
ates the preselected volume which is both in 
the sphere and the container. Β, Ή MR spec­
tra of the voxels in the pre-selected volume. 
The orientation is the same as in figure 7A. The 
nearly coinciding main citrate signals (Ci), and I 
signals of acetate (Ac) and glycine (Gl) are indi- .Â\ 
cated in the middle left voxel. The major lipid 
signals are indicated by 'Lip' in the lower right 
voxel. Spectra are plotted from 0-4 ppm 
В A 
Ci 
Gl Ас 
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Because we also have recorded the H..O signal for all volumes of which a spec­
trum was obtained, it is in principle possible to estimate tissue concentrations of 
metabolites using water as an internal reference. For this estimation it was 
assumed that the water content of prostate tissue is 83% and the tissue density 
1.02 kg/L [23]. Furthermore, it was arbitrarily assumed that 10% of tissue water 
is not recovered in the H 2 0 resonance of the MR recording at Те = 135 ms 
because of a short T2 e.g. due to macromolecular binding and other interactions, 
similar as described for brain MR studies [24]. By these calculations the average 
prostate tissue concentrations (per litre tissue volume) of cholines and creatine 
were estimated to be 3.1 ± 0.7 and 4.4 ± 0.8 mM respectively (n=10). 
Spectroscopic imaging (SI) measurements 
Phantom study 
Figure 7a shows a transversal MR image of the phantom also displaying the pre­
selected volume and the grid with SI voxels. The MRI intensity distribution within 
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the sphere follows the sensitivity profile of the endorectal coil. Fig. 7b shows spec­
tra obtained from the voxels within the preselected volume. T h e spectrum in the 
lower right corner only shows signal intensity arising from lipid protons of sun­
flower oil as expected for its location. Spectra of voxels completely located within 
the sphere show signals for citrate, glycine and acetate. Signal intensity varies as 
a function of the sensitivity of the surface coil. Notice that the outer lines of the 
citrate multiplet are nearly in antiphase which is in contrast with the single voxel 
measurements where the outer lines are more in phase. This is due to the differ­
ence in time between the 90° and first 180° slice selection pulses. T h e small, some­
times inverted lipid signals seen in the SI spectra are attributed to voxel bleeding. 
Spectra of voxels located partly in the sphere and partly outside show signal con­
tributions of citrate, glycine a n d acetate c o m p o u n d s and of lipids according to 
their partial volume extent of sphere and container. These results illustrate the 
quality of localisation by the present SI approach. 
Volunteer studies 
For the preselected volumes chosen in this study (about 12 cc) we obtained a H 2 0 
resonance linewidth at half m a x i m u m just below 10 Hz which appeared to be 
sufficient to obtain well-resolved signals in most voxels of the spectroscopic 
images. 
Figure 8 displays a transversal T2-weighted image through the prostate of a 
volunteer of 32 years at a level close to the veramontanum. Anatomical details 
such as peripheral zone, central gland and capsule are visible. Due to the young 
age of the volunteer the prostate is relatively small and distinction between 
peripheral zone and central gland is less p r o m i n e n t than usually seen at older 
age. T h e grid projected on the image identifies voxels from which spectra are dis­
played in figure 9. These voxels have been obtained after extrapolating spatial 
data from a 16 * 16 to a 32 * 32 matrix by zerofilling in two dimensions in k-space 
prior to Fourier transformation. 
Fig. 8. Transversal MR image sho­
wing the prostate of a 32 year old 
healthy volunteer. The slice thick­
ness was 5 mm. Spectroscopic 
imaging was performed for an 11 
mm thick transversal plane. It was 
centered at the same position, but 
extended about 3 mm at either side 
beyond the MRI slice borders. The 
preselected PRESS volume is indi­
cated by the white dashed box. 
Zerofilling in the spatial dimensions 
has been performed from a 16 χ 16 
to a 32 χ 32 matrix. The volume with 
voxels from which spectra are dis­
played in figure 9 is indicated by a 
solid black box. 
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Fig. 9. Spectra of an SI data set from the voxels as shown in fig. 8 (black box). The maximum of 
the Gaussian filter applied was 64 ms and the half-width 256 ms. To aid interpretation the most 
prominent features of prostate anatomy are indicated schematically. Tnglycende signals are indi­
cated by TG in the top corner spectra and in the bottom left spectrum. In the second row the 
central citrate resonance in the spectra are indicated by Ci. In the spectrum labelled A the methyl 
resonances for creatine (Cr) and choline (Ch) are indicated. Spectra are plotted from 0.1 to 4.1 
ppm. 
Figure 9 shows spectra from voxels in the black lined block in figure 8. O t h e r 
voxels from the pre-selected volume show almost only signals for periprostatic fat. 
Typical spectral profiles observed in the selected data set appear to be related to 
p r o m i n e n t features of the h u m a n prostate. High triglyceride signals are observed 
outside the prostate or at the capsule. So most of the intensity in the u p p e r row 
comes from triglycerides and very litde from prostate metabolites. Note the 
relative decrease of the triglyceride signal in the two middle spectra of this row 
which coincide with the location of the anterior fibromuscular b a n d which has a 
low signal intensity on T, and T 2 weighted MRI [25,26]. T h e left column also 
shows spectra mainly with signals of methylene triglyceride protons of 
periprostatic fat. In the second row from above signals of metabolites in the 
prostate become visible such as those for citrate methylene protons (at 2.63 p p m ) 
and choline and creatine methyl protons (at 3.21 and 3.03 p p m , respectively). 
Citrate signals are n o t observed outside the prostate. 
Figure 10 shows enlargements of spectra from the peripheral part of the 
prostate (A) and from the central gland area (B). Well-resolved resonances for 
methylene protons of citrate and for methyl protons of creatine and (phos-
pho) cholines can be observed. T h e central gland area in the selected slab pre­
dominan tìy is composed of the transition zone of the prostate, but it also includes 
a part of the central zone, the urethra, periurethral tissue and the fibromuscular 
band [25,26]. Notice that in both spectra the outer lines of citrate are nearly in 
antiphase, similar as found for the citrate signal in the phan tom study. 
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Fig. 10. A, Ή MR spectrum of the peripheral part of the prostate. It ¡s a blow-up from the spec-
trum labelled A in the third row of fig 9. Β, Ή MR spectrum of the central prostate gland. This 
spectrum is a blow-up of a spectrum from the same row labelled B. In = inositol, Ta = taurine, 
Ch = (phospho) choline, Cr = creatine, Ci = citrate, Glx = glutamine/glutamate. 
Spectroscopic images of similar quality as shown above were obtained from the 
prostate of 3 other volunteers (age 40-46 years). In all 4 volunteers voxels of 1 cc 
were selected both from the peripheral zone and the central / transition zone. 
In the latter voxels contamination with peripheral zone tissue was estimated to 
be less than 10%. The citrate/cholines, citrate/ (cholines + creatine) and chol­
ines/creatine signal integral ratios were determined by fitting of the spectral 
lines to Gaussian model functions. T, corrections were performed assuming 
similar apparent T, values for proton spins in peripheral and central gland as 
those determined in the single voxel measurements. The T, corrected values are 
in Table I, columns III and IV. The citrate signal ratios are significantly higher in 
peripheral gland compared to the central gland. The values for average citrate 
ratios of the central gland (column III) are closest to the values of citrate ratios 
obtained from single voxels (column II), which were deliberately positioned in 
the center of the prostate. 
Pulse lenghts and value in the PRESS sequence used for single volume 
acquisition are different from those used for SI experiments. Because this may 
affect the citrate signal we have compared both sequences in a study of the 
phantom. In these experiments the area of the main citrate signal with respect 
to those of the acetate and glycine resonances differed not more than 10% be­
tween both acquisition methods. 
Discussion 
In this study it is demonstrated that high quality 'II MR spectra can be recorded 
of the human prostate by the application of PRESS localization and an endo­
rectal surface coil. Results are presented of normal prostates in volunteers at an 
age before BPH starts to occur. 
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Most experiments were performed with a timing of the PRESS sequence (i.e. 
Te = 135 ms) which is nearly optimal for refocussing of the main multiplet signals 
of citrate and which in principle enables one to identify lactate signals if present. 
Spectra obtained at this echo time are also sufficiently depleted of broad com­
ponents to enable quantitative evaluation of metabolite signals. Ή MRS of 
volumes carefully located in the center of the prostate demonstrate that it is pos­
sible to obtain spectra with little or no signals between 0.5 and 2 ppm. High signal 
intensity in this chemical shift range, often seen in 'II MR spectra of the prostate 
in vivo, is likely dominated by contamination of triglyceride signals from peri­
prostatic fat. 
The spectra obtained at Te = 135 ms show almost only signal intensity for the 
methyl protons of cholines and creatine next to the dominating peak of citrate 
methylene protons. The presence of signals of these compounds could be anti­
cipated from in vitro extract studies, e.g. [8,10-12]. However, these studies also 
revealed the presence of other compounds in prostate tissue at comparable 
amounts, e.g. inositol, taurine, glutamine and glutamate and possibly poly-
amines. Due to T 2 relaxation and/or J modulation their signals are much 
attenuated in spectra obtained at Te = 135 ms. However, at shorter echo times 
additional signals appear which can be assigned to some of these compounds. In 
this respect the situation is much the same as for Ή MR spectra of the brain 
obtained by the PRESS sequence. At longer echo times signals for choline, 
creatine and N-acetylaspartate are essentially the only signals remaining in the 
spectra. 
In 'H NMR spectra of extracts of normal prostate tissue significant signals are 
observed for lactate [12,13]. However, the present in vivo results, obtained by 
single voxel acquisition at TE=135 ms, give no indication for such signals. Lactate 
may have become "NMR invisible" in vivo, for instance due to macromolecular 
binding, but more likely its presence in in vitro spectra is a consequence of the 
biopsy procedure. 
A study concerning normal prostate has been reported in which PRESS was 
used for localization in conjunction with a Helmholtz coil for signal reception 
[14]. In concurrence with our findings no signs for the presence of a lactate 
signal in spectra of the prostate were observed. Furthermore, slow J modulation 
of the main peaks of citrate in vivo was demonstrated. Due to improved resolu­
tion both this slow modulation as well as the faster modulation of the outer peaks 
of citrate could be monitored in the present study. 
It is known that substantial amounts of divalent cations such as Mg2*, Ca2+ and 
Zn2+ are present in prostatic fluid [18]. As observed in Ή NMR of citrate solu­
tions both the spin-spin coupling constant and the chemical shift positions of 
citrate signals are sensitive to pH, but much more to complexation of citrate with 
these cations [27]. The chemical shift position of citrate signals measured in vivo 
are similar to those measured in vitro in the presence of divalent cations which 
indicates that also in the prostate, citrate is complexed to these ions. 
In a few volunteers apparent relaxation times for water and metabolite proton 
spins in the prostate have been estimated. T, and T2 relaxation times for water 
proton spins are close to values published previously by Kjaer et al. [28]. Recently 
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spatially more precise T2 measurements have been made showing a longer T2 
relaxation time for the peripheral zone as compared to the central zone [29]. 
Our T 2 value is closest to that reported for the central zone which is in agreement 
with the location of the volumes from which the measurements have been made. 
The apparent T, and T2 relaxation times estimated for choline and creatine 
methyl proton spins are equal or somewhat shorter than T^ and T2 relaxation 
times of the corresponding proton spins in Ή spectra of the adult human brain 
[30]. For citrate methylene proton spins a relatively short effective T, value is 
found. As citrate efficiendy binds divalent cations [27] this may be caused by 
trace amounts of paramagnetic ions. The estimation of these relaxation times 
provides starting values to set sequence timing in Ή MRS studies of the prostate 
and to enable quantification of compound levels. 
Presently, little quantitative data of localized Ή MR spectroscopy of the 
healthy human prostate in situ is available. Most studies have been performed 
using the STEAM localization sequence [4,9,13,29,31]. In a recent paper by 
Kurhanewicz et al. [32] quantitative data on the ratio of the citrate signal with 
respect to signal intensity at the choline and creatine position in spectra of zonal 
regions of healthy volunteers are presented using both STEAM and PRESS. 
Although experimental and processing conditions are somewhat different from 
ours the mean ratios in both studies are fairly similar. Some estimates of the tissue 
content of citrate in the prostate have been made by localized Ή MRS [5,29], but 
adequate evaluation of the complex citrate signal and correction forj-modula-
tion and T 2 relaxation for this purpose have not been fully realized yet. 
Levels for choline and creatine compounds in the prostate have not been 
reported up till now. The concentrations for cholines and creatine in the prostate 
estimated by MRS in the present study are different from those determined for 
brain tissue by the same method. The estimated choline concentration is higher 
and the creatine concentration lower than in brain (see for instance [30] ). A sub­
stantial part of creatine in the prostate is phosphorylated [12,33,34]. The most 
likely locations for creatine are the various smooth muscle components in the 
prostate: i.e. stromal and capsular muscle cells and myoepithelial cells surround­
ing prostatic acini. 
Previously, we have performed 'H NMR of an extract of a normal prostate 
tissue specimen [12]. We have reanalysed data of this sample to enable compar­
ison with the present in vivo results. From a fully relaxed Ή NMR spectrum 
obtained from the sample at pH 7 the total creatine signal intensity (Cr) was 
determined. Furthermore the signal intensity between 3.15 and 3.28 ppm was 
determined including contributions of all methyl protons of various choline 
compounds (Cho) but excluding contributions of taurine, inositol and phos-
phoethanolamine protons. A Cho/Cr ratio of 1.81 was found which is only slight­
ly lower than the Cho/Cr ratio obtained by in vivo MRS measurements at Te=l 35 
ms. Because Cho and Cr methyl proton spins have similar T2 values, this indicates 
that the majority of signal intensity at about 3.2 ppm seen in spectra obtained in 
vivo at Te=135 ms originates from choline compounds. 
The results of the spectroscopic imaging experiments show that high quality 
spectra can be obtained simultaneously from multiple locations in the prostate. 
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T h e present acquisition time to record a SI data set with good signal-to-noise at 
a nominal resolution of 1 cc was 13 6 m m at a Tr of 1600 ms Obviously, based on 
the estimations of the effective T, relaxation times of the main resonances a 
better signal-to-noise per unit time can be achieved and thus spatial resolution 
may be enhanced T h e acquisition of Ή MR spectra ot the h u m a n prostate at a 
spatial resolution below 1 cc has been demonstrated to be possible [32,35] Such 
resolution may be n e e d e d to match with the complex anatomy of the h u m a n 
prostate and with the heterogeneity of prostate pathology 
Variations in resonance intensity for distinct morphological locations in the 
prostate become visible at a spatial resolution of about 1 cc Most striking is the 
lower relative level of the citrate signal in spectra from the centra l/ transition 
zone as compared to the peripheral 7one Recently, a similar difference in citrate 
signal levels between peripheral zone a n d central/transit ion zone has been 
observed in o ther MRS studies [29,32] T h e average citrate c o n t e n t in the peri­
pheral part of the prostate appears to be twice of the a m o u n t in the central part 
[29] T h e same increase is found for the relative citrate signal in the present 
study A higher citrate level in the peripheral zone presumably is related to the 
presence of more glandular elements in this area [25] 1 his also explains why in 
the single volume measurements the citrate ratios are the highest in cases with 
most contributions of peripheral zone tissue 
In conclusion, this study on healthy individuals shows that with PRESS local­
ization a n d an endorectal coil, it is possible to perform detailed MR spectro­
scopic investigations of a n u m b e r of metabolites in relevant parts of the h u m a n 
prostate Data obtained in this way may serve as a reference for clinical applica­
tions of Ή MRS to BPH and prostate cancer [32,35]. 
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Abstract 
Background 
Recently the potentials of magnetic resonance (MR) methods for non-invasive 
diagnosis and therapy evaluation of prostate cancer have improved substantially. 
In this study proton MR spectroscopy ( Ή MRS) is explored for the detection of 
cancer in the prostate. 
Patients and Methods 
Employing an endorectal probe localized Ή MRS and contrast enhanced MR 
imaging were performed of the prostate of healthy volunteers and of patients 
with benign prostatic hyperplasia (BPH) and/or prostate cancer (PCa). 
Results 
Ή MR spectra of the human prostate show 3 major signals: i.e. for citrate, 
creatine and choline compounds. For cancer tissue the average citrate/ choline 
signal ratio is significantly lower than for BPH and non-cancerous peripheral and 
central zone tissue, but individual ratios overlap with ratios for normal central 
zone and BPH tissue. Low citrate/choline ratios in tumour tissue correspond 
with early MR contrast enhancement. 
Conclusion 
Ή MRS has potential for non-invasive detection and follow-up of tumours in the 
prostate. 
Introduction 
It is common practice to verify the presence of cancerous tissue in the prostate 
by histology of biopsy material. However, this analysis may be subject to sampling 
errors [1] and does not provide much information on spatial heterogeneity and 
multifocality. Non-invasive modalities such as computer tomography and trans­
rectal ultrasound (without guided biopsies) have been of limited value for dia­
gnosis and therapy evaluation of prostate cancer [2]. Also MR imaging (MRI) is 
still of little use to detect PCa and to determine its extension, although the more 
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recent introduction of endorectal and body phased-array radiofrequency detec­
tion coils have enabled better possibilities to stage PCa [3,4,5]. The potentials of 
MR may be further improved by the use of more advanced methods such as 
dynamic Gd contrast enhanced MRI or MR spectroscopy (MRS). Several groups 
have started to perform image-guided proton MRS ('H MRS) of the human 
prostate with endorectal and/or phased-array coils [6-9]. In a 'H MRS examina­
tion spectra can be obtained of particular locations in the prostate with proton 
signals of several metabolites. In this way it provides a metabolic window on 
prostate tissue which may be used for in-situ characterization, diagnosis and 
therapy evaluation of prostate cancer (PCa). 
The most prominent metabolite signal in Ή MR spectra of the prostate is that 
of citrate, of which the tissue content has been reported as a potential marker to 
discriminate between the presence of PCa and benign prostatic hyperplasia 
(BPH) [10-16]. In vitro studies of human prostate specimens have demonstrated 
that the relative intensity of the methyl proton signals of (phospho) choline com­
pounds in 'II MR spectra of PCa tissue is increased [15,16] and our preliminary 
results indicated that this could also be observed in vivo [8 | . 
In this paper we report on results of the application of image-guided localized 
41 MRS in studies of the prostate of healthy volunteers, patients with BPH 
and/or with PCa. We applied and compared single and multiple voxel data 
acquisition methods. As elevation of choline and lowering of citrate levels appear 
to be associated with PCa, the citrale/choline (Ci/Ch) signal ratio plays a central 
role in the analysis of our data. Preliminary results on the combination of Ή MRS 
and dynamic contrast enhanced Gadolinium (Gd) MR measurements are also 
presented. 
Patients and Methods 
Volunteers and patients 
This study was approved by the local ethical committee and informed consent 
was obtained from all participants. Results of studies of 6 healthy volunteers aging 
from 32 to 54, without a history or clinical signs of prostate disease, are included 
in this report. MR images of the prostates were interpreted as being normal 
except for some slight hypertrophy of the oldest volunteer. Sixteen patients with 
BPH were included in this study (ages between 52 and 73). Furthermore, 23 patients 
suspected to have PCa, mainly on the basis of PSA levels (10 ng/ml or more) and 
ultrasonography, were investigated. The definitive diagnosis (PCa or not) was 
made on the basis of histological analysis performed on prostate tissue specimens 
obtained by needle biopsy or radical prostatectomy. Subjects were positioned 
supine in the magnet bore with a belt applied around the lower abdomen to 
reduce respiratory motion. Patients received 1 mg glucagon intravenously as anti­
peristaltic drug. 
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MR methods 
MR examinations were performed on a 1.5 Τ MR system (Magnetom SP, 
Siemens, Germany) employing a body radio-frequency coil for excitation. For 
MR signal reception a disposable endorectal probe (MEDRAD®, Pittsburg, USA) 
holding a surface coil, was inserted. The probe was inflated with air to ensure 
tight positioning of the coil adjacent to the prostate. 
MRI and MRS of the prostate was performed during the same patient 
examination which lasted about 1 hour. First multiple slice MR images were 
obtained in 3 orthogonal planes with a turbo spin-echo (TSE) sequence as 
described previously [5]. Guided by these images the prostate was inspected for 
the presence of areas likely to contain cancer tissue (hypo-intensity in the peri­
pheral zone and anatomical deviations). 
Localized Ή MRS was performed with a double spin-echo slice selective pulse 
sequence (PRESS [17,18]) preceded by water signal suppression which first was 
turned off to optimize field homogeneity. The echo-time (Te) was 135 ms. 
For single voxel MRS a voxel of nominal 1.5*1.5*1.5 cm (3.4 cc) was 
positioned in an area suspected to be tumour tissue, and if possible another voxel 
was studied in a non-cancerous area. The scan repetition time (Tr) ranged from 
1.6 to 4.5 s and the number of scans from 96 to 256. 
In the Ή MR spectroscopic imaging (SI) experiments an axial slab of 10 mm 
thickness, 40 (or 50) mm in the left-right and 30 (or 40) mm in the anterior-
posterior direction was selected using the PRESS sequence (Te = 120 - 135 ms) 
and positioned such that it contained a maximal amount of area suspected to be 
cancer tissue. Gradients for phase encoding in 2 directions were applied to 
obtain a multiple voxel SI data set within this preselected slab [19,20]. Data were 
encoded in a 16 * 16 matrix with a field-of-view of 144 or 160 mm, resulting in 
nominal voxels sizes of 0.8 or 1.0 cc. Per phase-encoding step 2 or 3 acquisitions 
were acquired with a Tr of 1.2 or 1.6 sec resulting in acquisition times of 13-15 
min. 
For eddy current correction and referencing purposes MRS experiments were 
also performed without water suppression. 
In a number of patients suspected of PCa a dynamic Gd contrast enhanced 
inflow MR measurement was performed [21,22] after the MRS measurements. 
An axial slice of 10 mm thickness was selected through the suspected tumour 
region at exactly the same location as the SI slab or coinciding with the position 
of the single voxel. MR images were obtained by a turbo FLASH sequence ( 1-2 s/ 
image) before and during inflow in the slice of Gd contrast, which was 
administered intravenously. 
Post-processing was performed as described elsewhere [23]. Metabolite maps 
were reconstructed from the intensities of citrate and choline proton signals in 
SI spectra, showing spatial distributions of these compounds. 
Chemical shifts are given in parts per million (ppm) with respect to the water 
resonance at 4.68 ppm. Signal integrals were determined by computer integra­
tion. All presented signal ratios for citrate and choline were corrected for T! 
weighting using an effective T, of 339 ms for citrate protons and of 837 ms for 
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choline protons as determined in a separate volunteer study [23]. Average values 
are presented with standard deviations (±SD). 
Dynamic Gd contrast enhanced MR experiments are presented as dynamic 
subtraction (DS) images obtained by subtracting MR images recorded during Gd 
inflow in the slice from control images recorded before inflow. 
Results 
In figure 1A a T2 weighted MR image is shown of an axial plane through the 
prostate of a patient with PCa. An enlarged central gland (BPH) can be observed 
as a hypo-intense area including some hyper-intense nodular elements. The peri­
pheral part of the prostate shows up as a hyper-intense zone except at the right 
side on this image where it is hypo-intense (solid box). This area was later 
demonstrated to be tumour tissue by histological examination. It showed earlier 
enhancement than other prostatic tissue on DS MR images (see arrow in Fig. 
IB)). Ή MRS was performed for voxels (see Fig. 1A) of which the spectra are 
shown in figures 1С and D. The spectrum in figure 1С, from a region assumed 
to house no cancer tissue, looks similar to spectra obtained from the peripheral 
zone of normal and most BPH prostates. It shows 3 major resonances. One at 
about 2.6 ppm originatíng from the methylene protons of citrate, one at about 
3.0 ppm originating from the methyl group of creatine and one at about 3.2 ppm 
to which methyl groups of various choline containing compounds contribute. 
These assignments are based on previous 'H MRS studies of perchloric extracts 
of prostate specimens [12-16]. The spectrum from the tumorous region (Fig. ID) 
shows a strongly reduced citrate signal and an apparenüy increased choline and 
decreased creatine resonance. 
Fifteen patients suspected of having PCa were examined by this single voxel 
approach. Two patients gave up further medical examinations after the MR 
investigation so that no definitive diagnosis is available and 3 were considered to 
have BPH after multiple biopsies. In 10 cases the presence of PCa was proven by 
histopathological examination of prostate material, either obtained by biopsy or 
radical prostatectomy [5]. After careful evaluation of the MR images and com-
parison with the histopathological results it was concluded that in 3 of these cases 
the voxels, with the aim to cover cancer tissue, were either located in an area with 
no apparent presence of cancer tissue or were mostly occupied with non-can-
cerous tissue (> 75%). For the 7 remaining cases it was estimated that the voxels 
mainly contained tumour tissue (> 50%). The citrate/choline signal ratio was 
determined from the spectra for further evaluation (see below). 
In 3 patients suspected of having PCA a dynamic Gd MRI measurement was 
performed after the single voxel 'H MRS examination showing relative fast 
enhancement in the area for which a low Ci/Ch signal ratio was determined. 
Flight patients suspected to have PCa were investigated by 2D SI in an axial slab 
through the prostate using similar experimental parameters as for the single 
voxel measurements. In figure 2 results of a 2D SI and a dynamic Gd MR 
examination are shown of a PCa patient. Figure 2a and b show T2 weighted MR 
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Fig. 1. Results of an MR examination of a patient with PCa (T3c, PSA 37 ng/ml). A, T2 weighted 
axial TSE image of the prostate. Boxes indicate the size and location of two selected voxels for 
*Η MRS. B, DS MR image showing focal enhancement (arrow) due to Gd contrast inflow in the 
tumour. The image is obtained at approximately 12 s after the start of inflow in the imaged slice. 
C, Ή MR spectrum of the volume indicated by the dashed box. D, 1H MR spectrum of the volume 
indicated by the solid box (tumor area). Ch = (phospho) choline, Cr = creatine, Ci = citrate. 
images of an axial slice. Metabolic maps, reconstructed from signals of the SI data 
set are overlaid on these images. O n the MR image a hypo-intense area in the 
peripheral zone is visible (arrow) extending into the prostate which was later 
identified as cancer tissue. T h e citrate metabolite m a p (fig. 2A) shows a relative 
low citrate level in this area. In contrast the choline metabolite m a p (fig. 2B) 
shows increased intensity. Fur thermore, DS-MR images from a dynamic (id MR 
investigation of the same slice showed fast e n h a n c e m e n t in this area (fig. 2C). 
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Fig. 2. Results of an MR examination of a pati­
ent with PCa (T3c, PSA 19 ng/ml) 
A, T2 weighted axial TSE image of the prosta­
te. The coloured overlay represents the distri­
bution of citrate content over the prostate 
reconstructed from a SI experiment at the 
same axial location (Te=120 ms, Tr=1200 ms). 
A hypo-intense region in the peripheral zone 
corresponding with tumour tissue is indicated 
by an arrow. B, Same T2 weighted image. The 
coloured overlay now represents choline con­
tent. C, DS time image showing enhanced 
intensity at the tumour region. 
Of the 8 patients suspected of PCa and investigated by SI, 5 were finally dia­
gnosed as having PCa on the basis of biopsy material or radical prostatectomy 
specimens [5]. Of 1 patient no final diagnosis could be obtained, while histopa-
thological examinations of biopsy material of 2 other patients showed no 
apparent malignancies. From the five SI data sets voxels were selected in ident­
ified cancerous areas and in areas assumed not to be affected by cancer. Ci/Ch 
signal ratios were determined from spectra of these voxels. 
Although generally the experiments indicate increased choline signals in 
tumorous regions, in some cases the choline signal actually seemed to be 
decreased in such regions (with respect to the signal of water as an internal refer­
ence), but because the citrate signal decreased much more, the Ci/Ch signal 
ratio still served as a potential marker of malignancy. 
The plot in figure 3 summarizes the evaluation of the Ci/Ch signal ratios 
derived from Ή MR spectra of normal prostates, BPH and PCa patients. It shows 
average values of this ratio and standard deviations obtained from SI experiments 
of the normal prostates of healthy volunteers (n=6). The Ci/Ch signal ratio 
A 
C) time 
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Fig. 3. Average Ci/Ch signal 
integral ratios (± SD) obtained 
from spectra of selected regi-
ons in the prostate. PZv : peri-
pheral zone normal prostate 
(n=6). Method: SI; CZv: cen-
tral zone normal prostate 
(n=6). Method: SI; BPH: 
mainly central gland (BPH 
region) of BPH patients 
(n=14). Method: SVS; PZp: 
normal peripheral zone of 
PCa and BPH patients (n=7). 
Method: SI; PCa: malignant 
tissue (n=12). Method: SI and 
SVS; SVS = single voxel 
spectroscopy; SI = spectros-
copic imaging 
values ranges from 2.2 to 5.4 for the peripheral zone and from 0.6 to 1.9 for the 
central zone. For BPH patients (n=14) the Gi/Ch signal ratio have been deter-
mined from single voxel measurements with mainly central gland tissue (BPH 
region) and shows a wide range of values: from 0.8 to 7.6. The range of values in 
non-tumour areas of peripheral zones of PCa and BPH patients determined with 
SI is from 1.7-3.5 (n=7) 
The average Ci/Ch signal ratio obtained of all single voxel plus SI spectra from 
tumour regions (n=12) is significanüy lower compared with each other group: 
peripheral zone, central zone and BPH regions (t tests: ρ < 0.002 for each com­
parison). However, the range of individual values (0.2-1.2) overlaps with the 
ratios obtained from central zone tissue in normal prostates and from BPH tissue. 
Discussion 
Citrate is highly abundant in the normal human prostate and mainly resides in 
the luminal space of the prostate [10]. For the normal prostate citrate signal 
levels are higher in Ή MR spectra of the peripheral zone than in spectra of the 
central gland (including the transition zone and periurethral tissue) [9,23,24]. 
This is also evident in this study and is related with the different amount of citrate 
secreting elements in both parts of the prostate. The large variation of relative 
citrate signals for central gland BPH tissue is most likely caused by differences in 
glandular and stromal contributions. This study shows that decreased relative 
levels of citrate in cancer tissue of the prostate can be detected by in vivo 'H MRS. 
Lower citrate levels found in cancerous tissue are presumably due to a reduction 
of citrate secreting epithelial structures [10,14,15]. 
Results from this and previous studies [8,15,16,24] indicate that the choline 
resonance is increased in cancerous areas of the prostate, but occasionally we 
have also observed reduced relative choline signals for PCa tissue in vivo. 
Citrate/choline signal ratio 
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Elevated signals for choline compounds have been reported n o m 'H MRS 
studies of brain tumours f 25 ] and are assumed to be related to a high prolifera-
tion rate of tumour cells. 
The average I ,-corrected c i t ra te /chohne signal ratio, which we used for quant-
itative purposes, appeals to be significantly reduced in tumour tissue compared 
to normal prostate and BPH tissue However, as there is overlap with values of 
BPH tissue and normal central / o n e , at the present status of MRS, the potential 
clinical applicability is restricted to peripheral zone tumours The results of this 
study generally are in good agreement with results published recently by 
Kurhanewicz et al [24] employing a similar MRS approach in 3 dimensions 
O n e cause of failure to correcdy place a volume of interest in a malignant 
region of the prostate by single volume MRS in a n u m b e r of cases is due to the 
fact that conventional MRI is not very reliable in depicting prostate tumours. This 
shows that a multiple volume method for MRS enabling post-acquisition spatial 
evaluation, as efficiently provided by SI methods, is essential Preferentially, 
spectra should be obtained from voxels covering the whole prostate at high 
spatial resolution [24] 
This studv also demonstrates that T2-weighted MRI, 'H MRS and dynamic Gd 
enhanced MRI can be combined in a single pauen t examination Dynamic Gd 
enhanced MRI has proven to be successful in the detection of some malignan-
cies [21] This is based on the specific (transient) accumulation of the contrast 
c o m p o u n d in tumour tissue ι elated to its typical neo-vascular characteristics 
Preliminary result!» indicate that it also improves prostate tumour detection 
(Chapter 5) Ή MRSI in combination with d\namic Gd contrast enhanced MRI 
may be helpful to improve the characterization of cancer in prostate tissue 
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8 The Current Role of MR Imaging in the 
Local Staging of Prostate Cancer, Future 
Research and Future Prospects 
G.Jager 
Introduction 
Before advocating the widespread use of MR imaging for selecting patients with 
prostate cancer for curative therapy, a thorough review and evaluation of the 
literature should be made, with particular emphasis on: 1 ) the true clinical need 
for MR; 2) whether implementation of MR will improve patient outcome; and 3) 
wether there is a real cost/risk/benefit justification. In the last decade an expo-
nential rise in the number of patients diagnosed with prostate cancer was seen. 
In the Netherlands, incidence and mortality of prostate cancer are exceeded only by 
those of lung cancer. In 1989, 4,112 incident cases and 2,079 deaths from cancer 
of the prostate were recorded in a male population of 7.5 million; this type of cancer 
caused 3% of total mortality among men and 10% of male mortality from cancer 
[1,2]. In most western countries the incidence increases with increasing age of 
the population, and public awareness of the disease. In the USA, prostate cancer 
incidence rate increased by 6.4% per year between 1983 and 1989 [3]. 
Prostate cancer is a relatively slow-growing malignancy, with the potential for 
local and distant spread. The prognosis is highly related to pathological stage, 
(gleason grade) and volume of the tumor at the time it becomes apparent. 
Although the tumor is slowly growing, a patient with prostate cancer will develop 
metastases and die of the disease if he lives long enough [4]. 
Ideally, clinical staging stratifies patients into comparable groups for definitive 
therapy and allows comparison of the effectiveness of different therapies, 
whereas pathological staging is important to predict prognosis and the need for 
additional therapy. 
Current opinion is that clinically localized prostate cancer can be treated suc-
cessfully by radical prostatectomy in the patient group with life expectancy of 10 
to 15 years or more. Nevertheless, benefits of aggressive treatment over watchful 
waiting in terms of quality-adjusted life expectancy are often small, lead-
ing to controversies about the best treatment [3,5-8] . 
Among men with prostate cancer, 60% have tumors apparently confined to the 
prostate [9,10]. However, clinical staging appeared to be unreliable. Under-
staging occurs in approximately 40% of the cases, and overstaging in about 20% 
[11]. Transrectal ultrasound did not improve clinically staging satisfactorily. 
Therefore we conclude that there is a clinical need for better staging of prostate 
cancer. The question we pose is if this has to be done by MR imaging. 
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Local staging of prostate cancer 
Since 1984 MR imaging has been used as staging modality for prostate cancer. 
The result are diverse and conflicting [12-14]. In the radiological literature the 
role of MR imaging in local staging is still under debate. At the moment, urol-
ogists in general do not advocate MR imaging for staging prostate cancer since 
they rely on transrectal ultrasound (TRUS) [15]. 
MR may be a substitute for TRUS if it is better and cheaper. If MR is better but 
more expensive (or cheaper but worse!) the relative merits have to be weighted. 
MR imaging versus TRUS 
To our knowledge two studies addressed the issue of comparing the staging effi-
cacy of the two current imaging modalities [ 16,17]. In the largest study published 
to date, by Rifkin et al. [ 18] (219 patients), body coil MR imaging was more sen-
sitive than TRUS for staging prostate cancer (77% vs 66%, respectively). However, 
this difference was not statistically significant. Another study reported a signif-
icant higher sensitivity of 91% for capsular penetration with MR imaging com-
pared to 48% for TRUS [17] 
At the moment TRUS is cheaper and better available than MR and there is too 
little evidence that staging results are better compared with MR. Even if staging 
accuracy with MR is significantly better than with TRUS, it is very unlikely for MR 
to replace TRUS. In general TRUS is also used to establish the diagnosis of 
prostate cancer by image guided transrectal biopsies. The results of the biopsies 
add important information about stage, grade, multifocality, tumor volume and 
seminal vesicle involvement. This is called biopsy-based staging [19,20]. Trans-
rectal MR guided biopsy devices are not expected to be available in short time. 
Conclusion: MR will be a complement to rather than a substitute for other 
staging modalities. The diagnostic impact of MR in prostate cancer staging may 
be to increase the clinical staging accuracy and to reduce the diagnostic uncer-
tainty. Therefore the question is: "Is there evidence that implementation of MR 
in staging prostate cancer is efficacious" 
Evidence based medicine 
Decision making in healthcare is a complex process, often strongly influenced by 
intuition and unsystematic clinical experience. In this example the decision to 
recommend MR in the local staging of patients who are a candidate for a radical 
prostatectomy. It has been emphasized that decisions should be made evidence 
based [21]. Guidelines and recommendations should be developed, based on 
strong evidence derived from literature. Evidence-based medicine requires new 
skills of doctors including efficient literature searching, critical appraisal of the 
literature, and the capability to assess the strength of evidence, guidelines and 
recommendations [21]. 
A randomized control trial (RCT) is considered the most powerful method for 
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assessing the effect of healthcare interventions. However, the use of RCT is 
limited in the evaluation of MR in prostate cancer. A rigorous randomized con-
trol trial requires a meticulous study design, a large number of patients (approx-
imately 1000), and a long follow-up time (15 years). Even differences in out-
comes between different treatment options are difficult to prove [22]. Due to 
rapid technical evolution with respect to coil design and pulse sequences the 
imaging method will be obsolete at the time the results become available. 
Also evidence may become available from observational studies such as case 
control studies and cohort studies. But none are available with respect to MR 
imaging of the prostate. Evidences of the weakest sort may come from expert 
panels [22J. For example in 1992 "the consensus workshop on screening and 
global strategy for prostate cancer", did not recommended MR as a staging tool 
[15]. However there are no estimates on what data the recommendations were 
based and no radiologists were involved in the development of this guideline. 
Decision analysis 
Another approach to define the role of MR imaging in prostate cancer is decision 
analysis. Decision analysis involves choosing an action after weighting the risks 
and benefits of the alternatives. A decision analysis should include information 
about pretest probabilities, test accuracy, treatment effectiveness, patient out-
come and about costs data with respect to diagnosis treatment and complica-
tions. Meta-analysis of the literature should provide data related to the natural 
history of disease, life-expectancy with and without therapy, complications of dia-
gnosis, complications of therapy, progression of the disease (local, distant) and 
so on. With these data costs and QALY (Quality-Adjusted Life-Years, see later) 
saved by introducing MR can be calculated and a cost/benefit analysis can be 
made. 
Modelling a decision tree always involves a compromise between simplicity 
and reality. A simplified decision tree, to evaluate patient's gain if MR is used to 
determine the indication for surgery, is helpful to unveil the complexity and pit-
falls of such an approach, (fig 1). 
Setting up a tree with a binary change node leads to eight outcomes. The rela-
tive frequency of each outcome can be calculated from sensitivity and specificity 
of MR for extra-prostatic disease and the prevalence of extra-prostatic disease in 
the patient population. In the cases A,B,G,H outcomes are not affected by the 
use of MR. The additional cost are of the MR examination and the benefits are 
more diagnostic certainty for doctor and patient. The advantage of latter is diffi-
cult to express in money [23]. 
In the other branches of this tree the decision is supposed to be affected by the 
results of MR. 
We assume positive effects in D and E; 
- No surgery because MR depicted a true-positive T3 
- Surgery because MR depicted a true-positive T2 
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Fig 1. Decision tree for two alternatives. Starting from the decision node far left The treatment 
decision is supposed to be determined by MR. See text for explanation. 
We assume negative effects in С and F; 
- No surgery because MR falsely predicted a T3 tumor 
- Surgery because MR falsely predicted a T2 tumor 
Values can be expressed in money and life years saved. This latter is measured by 
quality-adjusted life-years, (QALYs). A QALYis an expression of patients value of 
being in an ill state of health. This is quantified by the period in full time of health 
which for the patient, is equivalent to a year with illness. For example one year 
with impotence for one patient equals 6 months of full potency, for another 
patient this equals 9 months. If these patients live both 10 years after the radical 
prostatectomy the QALYs are respectively 5 and 7.5 years. Also the quality of life 
may change during the course of the disease, for example due to the devel­
opment of metastases. These effects are calculated with Markov modelling. With 
help of QALYs a patient can better chose between different treatment and allow 
health care providers to calculate the cost of a particularly procedure for every 
QALY saved. Many efforts have been made to measure and document life expect­
ancy [24], quality of life outcome [25], treatment costs [26], patients and doctors 
preference [10], complication rates for different treatment options [27,28]. Still 
little is known how the quality of life is affected by therapy [29]. 
Also, reality demands a more complex decision tree because; 
- Treatment decisions are dependent on patients and doctors preferences. 
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Fig 2. Starting from the decision node far left. A patient with prostate cancer. After initial scree­
ning the patient may be a good or a poor candidate for radical prostatectomy, depending on age, 
patients preference tumor grade and so on. There will be subtle gradations between these extre­
mes. In some of these patients the results of MR will not affect treatment. In other patients the 
results may seldom affect treatment. MR should not be recommended for these group, although 
for some individuals the results may be decisive for treatment. For patients in the central (B) part 
of the node. MR may be decisive. Future research has to determine this group. Value associa­
ted with the outcome of the two alternatives, operation or no operation, are not yet determined. 
- Patient population is diverse and patients have different pro-test probabilities 
of having high or low stage disease. 
- The results of the MR images will not equally affect therapy. This may vary from 
no influence to being decisive for treatment. 
- In practice the results of MR images are not expressed as a simple yes or no but 
given on a gradual scale varying from "without doubt" to "cannot be excluded". 
- Outcome is not solely dependent on clinical stage but also on other prognostic 
factors like grade, PSA, tumor volume, nuclear polymorph diploidisn, 
neovascularity and molecular factors like e-cadherin expression [30-331. 
- Patients with a limited T3 disease may still be a candidate for curative surgery 
A more realistic decision tree is shown in figure 2. Although much data are 
lacking, this figure suggests that MR may be useful in a subgroup of patients. One 
study addressed the question for which subgroup of patients MR may provide 
additional information concerning patients outcome following radical prosta­
tectomy [34]. This was the case in patients with a intermediate risk of seminal ves­
icle invasion or extracapsular extension (PSA s 20 ng/ml and Gleason sum 5—7, 
or the PSA level ^ 20 ^ 10, Gleason sum 2-4 predicted). 
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Medical technology assessment (MTA) 
Another approach to analyze the question if local staging with MR is appropriate 
is medical technology assessment (MTA). 
Ideally a diagnostic test should be adequately evaluated before widespread 
introduction in the medical society. Medical technology assessment (MTA) 
defines the clinical efficacy of a new diagnostic test. The basic definition of 
efficacy is "the probability of benefit to individuals in a defined population from 
a medical technology applied for a given medical problem under ideal condit-
ions of use" [35]. Efficacy overlaps partly with effectiveness, which reflects the use 
of a medical technology in ordinary clinical practice, rather than ideal condit-
ions. Fryback and Thornbury advocate a hierarchical model to study the efficacy 
of a diagnostic (imaging) method (tabel 1) [36]. 
Fryback's and Thornbury's Hierarchical Model of Efficacy 
Level 1 Technical efficacy 
Level 2 Diagnostic accuracy efficacy 
Level 3 Diagnostic thinking efficacy 
Level 4 Therapeutic efficacy 
Level 5 Patient outcome efficacy 
Level 6 Societal efficacy 
The first two levels describe efficacy in terms of physical image quality and dia-
gnostic accuracy. Level 3 and 4 assess the impact of diagnostic information on the 
clinician's thinking and acting; the clinical efficacy. Level 5 and 6 consider 
patient outcome and impact on the society. The levels are interconnected. 
Efficacy at lower level is, to a certain extent necessary, to ensure efficacy at a 
higher level. 
For technical efficacy case series with sample sizes ranging from 3 to 10 obser-
vations that correlate final diagnosis with MR images are sufficient to demon-
strate diagnostic capability. Many studies have demonstrated that MR imaging 
can provide high-quality images of the prostate. 
High-quality studies should have sufficient patients (from 35 to several 
hundreds) and an independent determination of disease state (gold standard) 
are necessary to determine diagnostic accuracy efficacy. 
It appeared to be difficult to differentiate between benign and malignant 
lesions especially for lesions located in the central zone of the prostate, nor was 
it possible to demonstrate a correlation between the tumor volume assessed on 
the MR images and histopathology [37]. Most reported MR studies have been 
focused on the differentiation between T2 and T3 tumours. There is a wide range 
of reported accuracy rates varying from 50% to 90%. 
However one should consider that most diagnostic tests are still inadequately 
appraised [38]. Results of staging studies were difficult to interpret and to com-
pare because there is a large variation in patient selection, technical aspects 
(pulse sequences, coil design), diagnostic criteria and pathological examination. 
Also the confidence intervals for the obtained sensitivity and specificity are 
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seldom reported and correction for work-up bias or verification bias is seldom 
provided. Test reproducibility is low, due at least to some extent, to a consider-
able interobserver variation [ 12,39]. Also there is learning curve [40]. 
The efficacy on a higher level (diagnostic thinking efficacy, therapeutic effic-
acy, patient outcome efficacy and society outcome level) have yet not been tested. 
Therefore, there are not enough data to date that indicate that the intro-
duction of MR imaging in prostate cancer will improve patient outcome and will 
be cost-effective. However, at the moment there is strong evidence that paden ts 
with gross capsular penetration or seminal vesicle invasion are no candidates for 
radical prostatectomy [9]. Excluding these paden ts from operation may be 
worthwhile. The all-in price for a radical prostatectomy in our hospital is about 
$ 10.000 and for MRI of the prostate $ 666. If we make a simple calculation, 
neglecting additional costs, then 1 or more patients out of 15 should be pre-
vented an operation by the use of MR imaging for the method to be cost-effec-
tive. Cost-effectiveness is at an intermediate level at short time. 
Recommendations for future studies and future prospects 
Patients with clinically localized prostate cancer can be divided in three sub-
groups on basis of PSA and Gleason's grade; Patients with low-risk, intermediate 
risk and high risk for capsular penetration or seminal vesicle invasion. Staging 
with MR may be only efficious in one of these subgroup of patients. Sensitivity is 
dependent on the prevalence of capsular penetration and seminal vesicle 
invasion. Therefore, it is important that studies evaluating the diagnostic per-
formance of MR should provide data about the spectrum of evaluated patients 
and provide test indices for reported clinical subgroup. 
Also studies that determine the influence of MR imaging on patient manage-
ment have to be performed next. Due to increasing life expectancy, awareness of 
doctors and patient for the disease and effective screening methods, the number 
of patients with early stage localized prostate cancer will rapidly increase the next 
years. A number of these patients will probably not benefit from surgical or rad-
iation therapy. Also more patients may prefer conservative therapy. This may 
create a need for a non-invasive monitoring of patients who are treated conserv-
atively. Therefore MR studies should focus on the definition and detection of 
prognostic factors. MR spectroscopy and dynamic imaging following contrast 
may have potentials for this purpose. 
General conclusion 
Because MR imaging still is in an experimental phase we do not advocate MR as 
a routine staging procedure. MR imaging of the prostate should be performed 
under the following conditions. 
- There should be an investigative setting. 
- Due to the learning curve a large number of patients, arbitrary 25 or 50 per 
year, is warranted. 
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- T h e results should be carefully compared with histopathology, preferable 
whole-mount sections 
- T h e effects on clinical thinking a n d patient outcome should be analyzed 
- studies should provide data about the spectrum of evaluated patients a n d 
provide test results for clinical subgroups 
- Data should be gathered from multiple institutions in a reasonable time to 
obtain sound evidences for s tandard protocols. Imaging strategies and guide­
lines should be developed by expert panels. 
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9 Summary and Conclusions 
Samenvatting en conclusies 
Summary 
Prostate Cancer represents a significant health problem in most western 
countries. Consequently the prostate is increasingly being studied by MR imag-
ing. 
The first goal of this study was to define whether MR imaging with an ERC 
technique is able to correctly predict the local stage of patients with prostate 
cancer. The second goal was whether a 3D imaging technique could correctly 
predict the presence of lymph node metastases in patients with prostate cancer. 
The third goal was to determine whether new MR techniques such as spectro-
scopy and dynamic imaging may help to define the presence and spadai extent 
of prostate cancer. Furthermore to assess if these methods have potential in the 
characterization of the tumor. 
The objective, value and controversies of local staging are discussed in chapter 
2. Staging is performed according to the revised TNM classification system. 
Generally spoken, a patient with prostate cancer may be cured of the disease if 
the tumor does not extend beyond the capsule of the prostate and if there are 
no distant metastases. However, with respect to the treatment of prostate carc-
inoma we are facing some controversies. Cure may be possible when there is 
microscopic capsular penetration while on the other hand, radical prostatectomy 
may not be the best treatment options for all patients with localized prostate 
cancer. Some patients with locally confined disease may better be "treated" by 
conservative management. 
Furthermore, pathological stage appeared not to be the sole predictor of out-
come in patients with prostate cancer. It is concluded that other prognostic 
factors such as PSA, histologic grade (Gleason), tumor volume, and neo-vascul-
arity should be incorporated in a staging algorithm. 
In chapter 3 the results of local staging with an ERC technique in 34 patients 
are described. The results are comparable with those from the literature. In our 
study, MR could correcüy predict pathological stage in 68% of the patients. 
Because in 70% of the cases capsular penetration not detected on MR images was 
less than 1 mm and probably did not affect the prognosis of these patients it was 
concluded that the technique may be helpful in selecting patients for curative 
therapy. Furthermore it was not possible to predict tumor volume correcüy. Also 
the pitfalls of MR imaging with an ERC-technique were discussed. 
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One of the pitfalls of MR imaging with an ERC is discussed in an interlude. 
This is a report of a case of a patient with prostate cancer who had also senile amy-
loidosis of the seminal vesicles, mimicking seminal vesicle invasion by prostate 
cancer on ERG-MR images. 
Chapter 4 reports the results of a 3-dimensional (3D) MR imaging technique 
in the evaluation of pelvic lymph nodes in 134 patients with prostate or bladder 
cancer. The sensitivity in patients with prostate cancer was 60%. This is high 
compared to other MR studies. The results of MR-guided FNAB biopsies were 
hopeful. 
The second interlude is a comment on an article in which is suggested that 
there is no role for imaging in lymph node staging of patients who are a cand-
idate for a radical prostatectomy. It is concluded that imaging is still worthwhile 
in a select group of patients who are at high risk for nodal metastases to spare 
them an operation. However, the criteria of what we call a lymph node metastasis 
should be changed. The upper limit of a normal sized lymph node should be 
lower than the generally accepted limits of 1 or 1.5 cm. 
In chapter 5 we evaluated the potential of a dynamic MR imaging technique 
after bolus injection of contrast material. The imaging results of 57 patients were 
compared to histopathology with respect to tumor location and capsular pen-
etration. Sixty-three contrast-enhanced MR images were obtained at intervals of 
1.2 or 2.4 seconds at one level. Lesions that enhanced early or demonstrated a 
steep slope of enhancement were regarded as malignant. We demonstrated that 
prostate cancer can be discerned due to earlier and faster enhancement than 
benign prostatic tissue. With this technique capsular penetration and tumor 
location could be demonstrated better than with T2-weighted FSE images. Al-
though these differences were not statistically significant, we conclude that the 
methods have potentials for clinical use. 
Chapter 6 Reports the results of proton spectroscopy in healthy volunteers. 
The presence of various metabolites such as choline, citrate and creatine could 
be observed. With a PRESS sequence it was possible to obtain high resolution 
single volume spectroscopy of the prostate. It was also possible to perform 
spectroscopy in a preselected slice of the prostate with a nominal resolution of 1 
cc. Differences in citrate-choline ratio's associated with normal zonal anatomy 
could be demonstrated. 
In chapter 7 the results of MRS in patients with benign prostatic hypertrophy 
and prostate cancer are presented. We demonstrated that prostate cancer often 
may be discerned by a lower citrate level in combination with a significant 
increase of the choline peak. The citrate-choline ratio's in malignant prostate 
tissue was significant lower than in benign tissue. 
Chapter 8 is a discussion about the role of MR in the local staging of patients 
with prostate cancer who are a candidate for radical prostatectomy and contains 
recommendations for future studies. 
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Conclusions 
MR Imaging is playing an important role in the imaging of prostate cancer. 
Despite initial optimism the accuracy of MR imaging in the detection of capsular 
penetration is low. A prospective study is however needed, to evaluate if patients 
with only a microscopic amount of tumor penetration have a worse prognosis 
compared to patients in whom the tumor is confined to the prostate. 
With a 3D MR imaging technique lymph nodes can be detected. However, the 
incidence of lymph node metastases is low and therefore the yield of lymph node 
staging is low. On the basis of clinical stage PSA and Gleason grade it can be es-
timated which patients are at risk for having lymph node metastases and 
consequently will benefit from imaging. 
Prostate cancer shows early and rapid enhancement following bolus injection 
of contrast. With fast MR imaging and the use of a subtraction technique tumor 
assessment can be improved. 
It is possible to obtain high resolution MR spectra from single volume as from 
selected slices of the prostate. With MR spectroscopy it is possible to discriminate 
prostate cancer from non-malignant prostatic tissue on the basis of metabolite 
levels, specifically citrate and choline. 
Presently prostate cancer is detected at a lower grade of malignancy and a 
lower tumor volume in more and more patients patients. They will probably not 
benefit from an operation. Furthermore patients today are more involved in 
treatment decisions. Therefore information about all prognostic factor should 
be available. Preferable this information should be obtained the less invasive as 
possible. 
With the use of MR techniques such as fast dynamic imaging and spectroscopy 
more information about the biological behaviour of the tumor may be obtained. 
At present a study on the correlation of dynamic enhancement and spectroscopy 
is ongoing. At this moment comparison between enhancement, spectroscopy 
and pathology is only possible on a single slice. However in the near future it will 
be possible to perform dynamic imaging and spectroscopy in a multislice 
manner. 
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Samenvatting 
Het doel van deze studie was drieledig. Ten eerste, de betrouwbaarheid vaststel-
len van kernspin tomografie, beter bekend als MRI, in combinatie met een 
endorectale spoel, voor de lokale stadiëring van prostaatkanker. Ten tweede, on-
derzoeken of met behulp van een 3-dimenbionale (3D) MRI techniek lymfklier-
metastasen opgespoord kunnen worden bij patiënten die voor een radicale pros-
tatectomie in aanmerking komen. Ten slotte, vaststellen of een tweetal nieuwe 
MR technieken, n.l. de dynamische opnametechniek na een bolusinjectie met 
contrast en MR spectroscopie, van waarde kunnen zijn om de aanwezigheid en 
uitbreiding van prostaatkanker aan te tonen en om de tumor te karakteriseren. 
Hel doel, de waarde en controverses van het lokaal stadiëren van prostaat-
kanker worden in hoofdstuk 2 besproken. Stadiëring gebeurt volgens het TNM 
classificatiesysteem. In zijn algemeenheid geldt dat een patiënt met prostaatkan-
ker genezen kan worden als de tumor binnen het kapsel van de prostaat beperkt 
blijft en er geen metastasen op afstand zijn (^ T2,N0). Opvattingen over de 
behandeling van prostaatkanker zijn echter niet eenduidig. Zo kan enerzijds 
genezing ook mogelijk zijn als er slechts sprake is van microscopische kapsel-
penetratie en anderzijds hoeft een radicale prostatectomie niet de beste be-
handeling te zijn voor alle patiënten met een klinisch beperkt prostaatcarci-
noom. Sommige patiënten met een lokaal beperkte tumor kunnen beter met 
radiotherapie of een afwachtend beleid behandeld worden. 
Verder blijkt dat het pathologische stadium niet alleen de prognose van de 
patiënt bepaalt. Andere factoren zoals PSA, histologische graad (Gleason), 
tumorvolume en neovascularisatie bepalen eveneens de prognose en zouden 
daarom in een stadiërings algorithme moeten worden opgenomen. 
In hoofdstuk 3 worden de resultaten van lokale stadiëring met een endo-rec-
tale spoel beschreven. De resultaten zijn vergelijkbaar met die uit de literatuur. 
Met behulp van MR kan het pathologische stadium in 68% van de patiënten cor-
rect bepaald worden. Omdat 70% van de op MR beelden gemiste kapselpenetra-
ties microscopisch was (^ 1 mm), werd geconcludeerd dal de MR techniek 
behulpzaam kan zijn bij het selecteren van patiënten voor curatieve therapie. Het 
is met deze techniek niet mogelijk het volume van de tumor betrouwbaar te voor-
spellen. Verder worden de valkuilen van MR beeldvorming met behulp van een 
endo-rectale spoel besproken. 
Eén van die valkuilen wordt besproken in een interludum. Dit is een casusbespre-
king van een patiënt met prostaatkanker die eveneens seniele amyloidosis van de 
vesícula seminalis had. Dit werd op de MR afbeeldingen met een endorectale 
spoel ten onrechte genterpreteerd als invasie van tumor in de vesícula seminalis. 
Hoofdstuk 4 doet verslag van de resultaten van een drie-dimensionele MR 
opnametechniek ten behoeve van de evaluatie van perviene lymfklieren bij 134 
patiënten met prostaat-of blaaskanker. Bij patiënten met prostaatkanker was de 
sensitiviteit 60%. Dit is hoog vergeleken met andere MR studies. In dit hoofdstuk 
worden ook de eerste resultaten besproken van MR geleide biopsiën van ver-
dachte klieren. Deze eerste resultaten zijn hoopvol en vergelijkbaar met de resul-
taten van de gangbare (ΤΓ techniek. 
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Het tweede interludum is een commentaar op een artikel waarin werd gesug-
gereerd dat er geen rol is voor lymfklierstadiëring met beeldvormende technie-
ken bij patiënten die kandidaat zijn voor een radicale prostatectomie. Geconclu-
deerd wordt dat beeldvormende technieken waardevol zijn bij een selecte groep 
van patiënten die een groot risico hebben op lymfkliermetastase. Bij een aantal 
van hen kan een onnodige operatie worden voorkomen. Het criterium voor de 
grootte van een lymfkliermetastase moet lager zijn dan de nu geaccepteerde 
limieten van 1 of 1,5 cm. 
Hoofdstuk 5 bevat het verslag van de evaluatie van één dynamische opname-
techniek na bolusinjectie van contrast. De resultaten van de MR opname werden 
vergeleken met de histo-pathologische bevindingen vooral ten aanzien van 
tumorlokaüe en kapselpenetratie. Drie en zestig opnamen op een niveau werden 
verkregen met een tijdsinterval van 1.2 of 2.4 seconden tijdens een intraveneuze 
bolusinjectie met contrast. Afwijkingen die een vroege en/of snelle aankleuring 
lieten zien werden als maligne beschouwd. Wij toonden aan dat prostaatkanker 
kan worden onderscheiden van benigne weefsel door de vroege en snelle aan-
kleuring. Met deze techniek was kapselpenetratie en tumorlokalisatie beter aan-
toonbaar dan met de gangbare T2-gewogen opname. Hoewel de verschillen sta-
tistisch niet significant waren, concluderen wij dat de methode mogelijkheden 
heeft voor klinisch gebruik. 
Hoofdstuk 6 doet verslag van de resultaten van protonspectroscopie bij gezon-
de proefpersonen. De aanwezigheid van verschillende metabolieten zoals choli-
ne, citraat en kreatine kon worden waargenomen. Met een PRESS-sequentie was 
het mogelijk om spectroscopische metingen met een hoge resolutie van de pros-
taat te verkrijgen. Ook was het mogelijk om spectroscopische opnamen van één 
vlak te vervaardigen met een spatiele resolutie van 1 cc. Verschillen in citraat-cho-
line ratio's, geassocieerd met de normale anatomie konden worden aangetoond. 
In hoofdstuk 7 worden de resultaten van MR spectroscopie bij patiënten met 
BPH en met prostaatkanker gepresenteerd. Wij toonden aan dat prostaatkanker 
in het algemeen gekarakteriseerd wordt door een lager citraat gehalte gecom-
bineerd met een verhoogd cholinegehalte. In vergelijking met het weefsel van de 
normale prostaat en de prostaat met BPH is de citraat-choline ratio significant 
lager in tumorweefsel. 
Hoofdstuk 8 is een discussie over de rol van MR bij het stadiëren van prostaat-
kanker. Met behulp van een beslisboom en principes uit de "MTA" (Medical 
Technology Assessment) wordt met gegevens uit de literatuur bekeken of er ge-
noeg reden is om algemene toepassing van MR bij de stadiëring te propageren. 
De conclusie is dat deze techniek, ondanks veelvuldig gebruik, zich nog steeds in 
een experimenteel stadium bevindt. Wel zijn er sterke aanwijzingen dat met deze 
techniek bij patiënten met een beperkt risico op lokale uitbreiding ( matig gedif-
ferentieerde tumor met een PSA ^ 10, en goed gedifferentieerde tumor met een 
PSA s 10, ^ 20) een verbetering van de klinische stadiëring wordt verkregen. 
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Conclusies 
Afbeelding met MR speelt in toenemende mate een belangrijke rol bij de diag-
nostiek van prostaatkanker. De nauwkeurigheid van MR voor microscopische 
kapselpenetratie is laag. Patiënten met evidente kapsel penetratie hebben een 
slechtere prognose dan patiënten bij wie de tumor tot de prostaat beperkt blijft. 
Een prospectieve studie is nodig om te onderzoeken of de prognose van patiën-
ten met slechts microscopische tumorpcnctratie ook slechter is dan die van 
patiënten met een beperkte tumor. 
De onderzochte drie-dimensionele MR afbeeldingstechniek is gevoelig bij het 
opsporen van lymfkliermetastasen. Omdat de incidentie van lymfkliermetastasen 
laag is, is de opbrengst van routine stadiëring ook laag. Op basis van klinisch sta-
dium, PSA, en histologische graad (Gleason) moeten patenten geselecteerd wor-
den bij wie beeldvorming zinvol is. 
Prostaatkanker vertoont een snelle en vroege aankleuring na bolusinjectie van 
contrast. Met een snelle opnametechniek en het gebruik van subtractie kan de 
tumor beter worden beoordeeld. 
Het is mogelijk om een spectroscopische opname met een hoge resolutie van 
een enkel volume, of een geselecteerde snede van de prostaat te verkrijgen. Met 
spectroscopie is het mogelijk om onderscheid te maken tussen kanker en benig-
ne weefsel op basis van de citraat/choline verhouding. 
Momenteel wordt prostaatkanker bij meer patiënten in een vroege fase gecon-
stateerd. Deze tumoren zijn vaak goed gedifferentieerd en hebben een klein 
volume. Deze patiënten hebben mogelijk geen baat bij een operatie. Omdat 
patiënten vandaag de dag meer betrokken willen worden bij de besluitvorming 
rond de behandeling zal zo veel mogelijk prognostische informatie beschikbaar 
moeten zijn. Bij voorkeur dient deze informatie op een zo min mogelijke inva-
sieve manier verkregen te worden. 
Met behulp van MR technieken zoals snelle dynamische opnames en spec-
troscopie kan meer informatie over het biologische gedrag van de tumor worden 
verkregen. Op dit moment is een studie gaande naar de correlatie tussen snelle 
aankleuring en spectroscopie. Thans is vergelijking tussen aankleuring, spectro-
scopie en histopathologic slechts mogelijk in één vlak. In de toekomst zullen ech-
ter de dynamische opnamen en de spectroscopie techniek op meerdere snedes 
tegelijk toegepast kunnen worden. 
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Stellingen 
behorende bij het proefschrift: 
Magnetic Resonance in Prostate Cancer: 
Clinical Potentials 
Gebruik van een 3D-opnametechniek is het meest betrouw-
baar voor het opsporen van lymfkliermetastasen in het kleine 
bekken (dit proefschrift). 
MR opnamen van de prostaat met contrast hebben alleen zin 
indien van een snelle dynamische opnametechniek gebruik 
gemaakt wordt (dit proefschrift). 
Beeldvorming van lymfklieren heeft alleen zin wanneer bij 
verdenking op een métastase, bevestiging van de diagnose 
middels een dunne naaldbiopsie plaatsvindt (dit proefschrift). 
Bij proton MR spectroscopie kenmerkt prostaatcarcinoom 
zich door een verlaagd citraat- en een verhoogd cholinegehalte 
(dit proefschrift). 
Omdat prostaatcarcinoom in een steeds vroeger stadium 
wordt ontdekt, is het nodig patiënten die waarschijnlijk nooit 
last van het carcinoom zullen krijgen te onderscheiden van 
hen die behandeling behoeven (dit proefschrift). 
Het stellen van een diagnose mag nooit een doel op zichzelf 
zijn. 
Het laagdrempelig karakter van echografie voor de diagnose 
diepe veneu/e trombose leidt tot een paradoxale stijging van 
het aantal flebografieen. 
Subcutaan emphyseem van het bovenbeen wijst meestal op 
een ernstige intra-abdominale aandoening en vereist direct 
nader onderzoek middels een abdominale CT. 
üoor de enorme toename van nieuwe en vaak duurdere 
diagnostische technieken is het wenselijk dat het vak medische 
besliskunde onderricht en geëxamineerd wordt tijdens de 
opleiding tot basisarts. 
Voor een radiodiagnost is een analytisch denkvermogen en 
een goede visus essentieel. Het is daarom tegennatuurlijk dat 
hij voor het voltooien van een proefschrift vaak het verstand 
op nul en de blik op oneindig moet zetten. 
Een onderzoek met goede resultaten wordt vaak verward met 
een goed onderzoek. 
De beschrijving "De echo-specialist heeft twee enorme flap-
oren en in elk oor steekt een gehoorapparaat" * toont nog-
maals aan dat echo meer om te kijken dan om te luisteren is. 
Lidy Nicolasen, de Volkskrant 16 september 1995 
13. Wanneer een tennisspeler die omwille van het belasting-
klimaat in Monaco is gaan wonen een lintje ontvangt, dient hij 
zelf en niet de nederlandse belastingbetaler de produktie-
kosten te betalen. 
14. Wanneer boeren doorgaan met ongecontroleerd injiciëren van 
mest in de bodem, kunnen zij vanzelf binnenkort niet meer de 
kop in het zand steken voor de gevolgen van dit beleid. 
15. Kamerleden die menen dat het voor een beter contact met de 
samenleving nodig is om een commissariaat te vervullen, heb-
ben inderdaad een beter contact met de samenleving nodig. 
16. Het niet opnemen van een dankwoord in een proefschrift wil 
zeggen dat woorden tekort schieten. 
Gerrit Jan Jager 
Nijmegen, 11 december 1996. 



